gilead sciences inc annual report filed period ending address lakeside dr foster city california telephone cik industry biotechnology drugs sector healthcare fiscal year securities exchange commission washington dc mark one x annual report pursuant section securities exchange act fiscal year ended december transition report pursuant section securities exchange act transition period commission file gilead sciences inc exact name registrant specified charter delaware state jurisdiction irs employer identification incorporation organization lakeside drive foster city california zip code address principal executive offices registrant 's telephone number including area code securities registered pursuant section b act none securities registered pursuant section g act common stock par value title class indicate check mark whether registrant filed reports required filed section securities exchange act preceding months shorter period registrant required file reports subject filing requirements past days yes x indicate check mark disclosure delinquent filers pursuant item regulation sk section chapter contained herein contained best registrant 's knowledge definitive proxy information statements incorporated reference part iii amendment yes x aggregate market value voting stock held nonaffiliates registrant based upon closing price common stock nasdaq stock market february number shares outstanding registrant 's common stock february documents incorporated reference specified portions registrant 's definitive proxy statement filed commission pursuant regulation connection annual meeting incorporated reference part iii report based closing price per share excludes shares registrant 's common stock held executive officers directors stockholders whose ownership exceeds common stock outstanding february exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrant february registrant implemented twoforone stock split form stock dividend share per share amounts periods presented restated reflect splitpart item business forwardlooking statements risk factors report includes forwardlooking statements particular statements expectations beliefs plans objectives assumptions future events performance contained incorporated reference report based forwardlooking statements current expectations future events believe expectations reasonable forwardlooking statements inherently subject risks uncertainties many beyond control actual results may differ materially suggested forwardlooking statements various reasons including discussed report heading risk factors given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof undertake specifically decline obligation update statements publicly announce results revisions statements reflect future events developments overview gilead independent biopharmaceutical company dedicated discovering developing manufacturing commercializing proprietary therapeutics antiviral antiinfective oncology applications currently derive revenue four approved products five products development adding existing portfolio compounds internal discovery active product acquisition inlicensing strategy internal discovery activities include identification new molecular targets target screening medicinal chemistry also expertise liposomal drug delivery technology use develop drugs safer easier patients tolerate effective expanded business intend continue expand acquisition activities four products currently marketed us various countries worldwide ambisomeregistered trademark approved sale countries treatment prevention lifethreatening fungal infections copromote ambisome us fujisawa healthcare inc tamiflutm sold corporate partner hoffmannla roche countries treatment influenza recently received us fda approval prevention influenza vistideregistered trademark approved sale countries treatment cmv retinitis aids patients daunoxomeregistered trademark approved sale countries treatment aidsrelated kaposi 's sarcoma sales force us promote ambisome vistide daunoxome sales force europe australia promote ambisome daunoxome also corporate partners distributors promoting products countries believe advanced clinical candidate tenofovir df oncedaily pill taken part combination therapy treat hiv infection could address significant unmet medical need recently announced preliminary data ongoing phase iii clinical trial suggesting weeks treatment tenofovir df reduced hiv levels treatmentexperienced patients average approximately reduced viral levels undetectable levels approximately patients improved patients ' immune systems gathering data ongoing trials anticipate filing approval tenofovir df us europe mid retained commercial rights tenofovir df receive marketing approval promote us european sales forces studying adefovir dipivoxil two phase iii trials treatment hepatitis b virus infection hbv believe adefovir dipivoxil potential address many limitations current hbv therapies notably drug resistance associated longterm therapy conducting phase ii program nx relapsed ovarian cancer small cell lung cancer evaluating two oncology compounds preclinical studies marketed products products developed commercially available include ambisome drug treating preventing lifethreatening fungal infections tamiflu drug treating preventing influenza vistide drug treating cmv retinitis aids patients daunoxome drug treating aidsrelated kaposi 's sarcoma products sold indications approved vary product country region sold earned revenues approximately million sales products amount sales ambisome generated aggregate product sales royalty revenues approximately million total revenues earned revenues sales royalties products us million million million outside us earned revenues sales royalties products million million million begin recognizing revenues sales tamiflu ambisome ambisome liposomal formulation amphotericin b amphotericin b powerful antifungal agent known ability attack kill broad variety lifethreatening fungal infections also serious side effects including kidney toxicity patients likely suffer fungal infections patients weakened immune systems including transplant patients patients infected hiv virus cancer patients undergoing chemotherapy studies show delivering amphotericin b proprietary liposomal formulation ambisome reduces rate severity kidney toxicity injectionrelated reactions allows patients receive higher effective doses amphotericin b ambisome approved sale countries including us european union rest europe australia canada several countries latin america asia ambisome primarily used treating patients known lifethreatening fungal infections ambisome also approved us countries treat patients certain symptoms presumed fungal infections either first choice therapy first line traditional amphotericin b failed used us ambisome also approved first line treatment acute cryptococcal meningitis aids patients addition ambisome approved five countries precautionary treatment preventing fungal infections liver transplant patients approved treating rare parasitic infection called visceral leishmaniasis several countries countries ambisome approved including us authorized promote ambisome first line treatment patients known fungal infection countries ambisome approved use traditional amphotericin b therapy fails traditional amphotericin b useda second line therapy us copromote ambisome fujisawa healthcare domestic sales force agreement fujisawa entitles us percentage revenues generated sales provides fujisawa purchases ambisome us manufacturing cost see collaborative relationshipsfujisawa major european countries australia sell ambisome international sales force also sell ambisome independent distributors number countries europe latin america asia corporate partner sumitomo studying amibisome clinical trials japan sumitomo exclusive right sell ambisome japan receive percentage revenues receive sales see collaborative relationshipssumitomo revenues ambisome europe expect case foreseeable future major european countries sell ambisome currency country revenues us dollars could therefore decrease value currencies decrease relative value us dollar traditional amphotericin b significant competition ambisome many countries ambisome prescribed traditional amphotericin b therapy failed used addition lipidbased formulations amphotericin b compete ambisome significant lipidbased amphotericin b product currently competes ambisome abelcet drug sold elan corporation plc company significantly greater resources traditional amphotericin b significantly less expensive ambisome abelcet also less expensive ambisome expect face significant competition new antifungal products including caspofungin product developed merck received marketing approval january voriconazole developed pfizer inc pfizer filed application marketing approval voriconazole see competition tamiflu tamiflu oral pill treatment prevention influenza b tamiflu new class prescription drugs called neuraminidase inhibitors act disabling common strains flu virus preventing virus spreading patient tamiflu originally approved fda october treatment uncomplicated influenza adult patients november approved fda prevention influenza adults adolescents years older december tamiflu approved japan treatment influenza adults us treatment children young oneyear old used approved treatment influenza tamiflu shown reduce duration flu adults average days reduce severity flu symptoms incidence secondary infections taken approved prevention influenza studies shown tamiflu effective preventing development flu common side effects associated tamiflu mild nausea vomiting hoffmannla roche corporate partner developed tamiflu us exclusive right sell tamiflu began selling tamiflu us november may hoffmannla roche submitted marketing authorisation application european commission seeking tamiflu approved centralized procedure european union european application withdrawn hoffmannla roche enable hoffmannla roche submit additional data application refiled hoffmannla roche february certain application approved receive percentage net revenues hoffmannla roche generates sales tamiflu see collaborative relationshipshoffmannla roche several products available treat flu time shown effective safe neuraminidase inhibitors relenza antiflu drug sold glaxosmithkline neuraminidase inhibitor approved fda drug delivered inhaled powder direct significant competition tamiflu tamiflu currently fdaapproved neuraminidase inhibitor available pill believe method delivery gives tamiflu competitive advantage relenza aware however johnson johnson developing neuraminidase inhibitor potential delivered oncedaily pill tamiflu taken twice daily treatment flu johnson johnson receives approval product also direct significant competition tamiflu see competition tamiflu marketed alternative influenza vaccinations influenza vaccinations remain effective method preventing flu vistide vistide antiviral medication treatment cmv retinitis patients aids cmv retinitis condition caused viral infection characterized lesions form patient 's retina condition affects persons weakened immune systems common patients aids left untreated cmv retinitis lead blindness vistide approved fda june european regulatory authorities may based clinical trials demonstrating drug delays progression cmv retinitis lesions newly diagnosed patients previously treated patients failed therapies sell vistide us sales force therapeutic specialists five regional directors specialists promote vistide direct contact physicians hospitals clinics healthcare providers involved treatment patients cmv retinitis sell vistide wholesalers specialty distributors sell product us healthcare providers see marketing sales outside us pharmacia corporation exclusive right sell vistide vistide approved sale countries european union well several countries throughout world pharmacia corporation pays us percentage revenues generates sales vistide see collaborative relationshipspharmacia corporation several products compete vistide ganciclovir sold roche laboratories widely prescribed drug treatment cmv retinitis ganciclovir available injectable oral formulations oral formulation approved preventing treating cmv retinitis device marketed bausch lomb incorporated implanted patient 's infected eye releases ganciclovir directly infected area addition astrazeneca sells injectable drug treatment cmv retinitis called foscarnet cibavision sells cmv retinitis drug called fomivirsen injected directly eye believe sales vistide lower future periods cmv retinitis market continues decline due success combination antiretroviral drug therapies treating hivinfected patients significant side effect associated use vistide kidney toxicity due side effect certain precautions must taken vistide used certain circumstances vistide may used time vistide given patient patient must first tested warning signs kidney toxicity patient warning signs kidney toxicity vistide may given patient combination certain solutions reduce possibility kidney toxicity addition vistide may given patients receiving drugs cause kidney toxicity patients receiving drugs known cause kidney toxicity must discontinue taking drugs wait seven days using vistide certain animal studies cidofovir active ingredient vistide caused cancer side effects dosing limitations competitive disadvantage vistide exclusive worldwide license patent rights related technology cidofovir iocbrega obligated pay net revenues sales vistide products containing cidofovir iocbrega see collaborative relationships iocbrega daunoxome daunoxome liposomal formulation anticancer agent daunorubicin received approval sell daunoxome us countries first line therapy treating patients suffer hivassociated kaposi 's sarcoma kaposi 's sarcoma disease characterized widely disseminated lesions skin mucous membranes lymph nodes viscera life threatening patients suffering aids daunoxome uses proprietary liposomal technology deliver safer effective doses daunorubicin disease site studies shown daunoxome may actually locate accumulate patient 's tumor allow patient receive higher concentrations daunorubicin disease site could obtained equivalent dose nonliposomal daunorubicin daunoxome marketed us abroad therapeutic specialists certain foreign countries distributors believe sales daunoxome lower future periods number hivinfected patients develop kaposi 's sarcoma declined significantly recent years due success combination therapies treating hiv patients products late stage clinical trials two product candidates developing large latestage human clinical trials tenofovir df treating patients hiv adefovir dipivoxil treating patients hbv phase iii clinical trials successful apply fda foreign regulatory agencies approval sell drugs based results date expect apply fda european union approval tenofovir df mid addition january acquired exclusive rights market cidecintm european countries cidecin antibacterial developed cubist pharmaceuticals inc phase ii phase iii clinical trials cubist 's phase iii clinical trials successful apply regulatory approval cidecin europe however determine certainty clinical trials successful successful whether fda regulatory agencies approve drugs marketing tenofovir disoproxil fumarate tenofovir df nucleotide analogue reverse transcriptase inhibitor given daily part combination therapy treat hiv infection february announced preliminary week data study week phase iii clinical trial evaluating mg dose tenofovir df component combination therapy treatmentexperienced patients sites us europe australia designed study provide us conclusive data safety efficacy dosage tenofovir df study patients randomly divided two groups one group patients tenofovir df added existing combination therapy twothirds enrolled patients one group patients given placebo addition existing therapy onethird enrolled patients results suggest following weeks treatment tenofovir df reduced patients ' hiv viral loads average approximately log primary endpoint trial tenofovir df suppressed hiv viral loads undetectable levels approximately patients compared patients received placebo tenofovir df increased patients ' cd cell counts patients received placebo cd cell counts decrease increase cd cell count important indication hiv drug improving patient 's immune system rate patients discontinued use tenofovir df equivalent discontinuation rate placebo tenofovir df cause significant increase serious side effects relative placebo september presented results week phase ii dose ranging clinical trial tenofovir df treatmentexperienced patients study patients received one three doses tenofovir df mg mg mg placebo addition existing combination therapy week patients receiving placebo switched mg dose trial showed patient population following weeks treatment higher doses tenofovir df associated lower levels hiv compared placebo week higher doses tenofovir df associated lower levels hiv compared baseline measurement point greatest reduction observed mg group study also showed weeks dosing tenofovir df result increase serious adverse events preliminary phase iii results combined completed phase ii results support belief tenofovir df important treatment option difficult treat patients expect data trials together data clinical trials form basis marketing applications treating patient population expect file us europe mid january completed enrollment patients study phase iii clinical trial evaluate tenofovir df treating patients prior hiv therapy study compare safety efficacy treatment tenofovir df combination lamivudine tc efavirenz safety efficacy treatment stavudine dt lamivudine efavirenz study help us determine potential role tenofovir df treating patient population successful form basis supplemental marketing application use certain data obtained clinical trials support regulatory approval tenofovir df fda regulatory authorities could reject marketing application number reasons including require higher level safety efficacy data anticipated disagree design interpretation trials one major challenges treating hivinfected patients drug resistance many existing therapies treating hiv aids rely similar drug processes patients developed resistance one drug often develop resistance drugs within class believe tenofovir df eventually approved fda could important drug treatmentexperienced patients available data shown patients develop rapid resistance tenofovir df tenofovir df effective treating patients developed resistance therapies certain however resistance data may obtain upon completion phase iii clinical trials show similar resistance characteristics preliminary data study data obtained limited phase ii clinical trials another major concern hiv treatment convenience dosing combination therapies positive impact health hivinfected patients require patients take numerous different drugs drugs require multiple doses every day many timing restrictions results inconvenience patients also contributes patients missing doses adhering therapy believe tenofovir df administered oncedaily oral pill schedule may appealing hiv patients physicians low discontinuation rate observed tenofovir df study supports belief december discontinued developing adefovir dipivoxil treating hivinfected patients decision followed recommendation fda advisory panel approve mg dose adefovir dipivoxil treating hiv due primarily concerns kidney toxicity developed late trials well desire additional evidence treatment benefits tenofovir df structure activity similar adefovir dipivoxil tenofovir df associated kidney toxicity shown superior treatment benefits clinical trials certain kidney toxicity issues occurred later stages phase iii clinical trials adefovir dipivoxil arise clinical trials tenofovir df achieve adequate treatment benefits exclusive worldwide license patent rights related technology tenofovir df iocbrega would obligated pay net revenues sales tenofovir df iocbrega countries product patent protection see collaborative relationshipsiocbrega adefovir dipivoxil hepatitis b hepatitis b highly contagious viral infection cause acute liver failure patients develop chronic infection many years lead complications cirrhosis cancer lead death world health organization estimates approximately million people worldwide infected chronic hbv including million people united states adefovir dipivoxil nucleotide analogue reverse transcriptase inhibitor adefovir dipivoxil disables hbv virus interfering activity enzyme known hbv polymerase necessary hbv virus replicate randomized doubleblind placebocontrolled phase ii clinical trials mg dose adefovir dipivoxil reduced median hbv viral load approximately log twelve weeks treatment two separate phase iii clinical trials evaluate safety effectiveness adefovir dipivoxil pills treating patients chronic hbv infection phase iii trials designed randomized doubleblind placebocontrolled studies conducted clinical sites us canada europe australia southeast asia one trials fully enrolled patients evaluating adefovir dipivoxil daily mg mg treating patients test positive hbv e antigen common type hepatitis trial fully enrolled patients evaluating adefovir dipivoxil daily mg treating patients type hbv known precore mutant hepatitis b precore mutant hbv common countries southeast asia mediterranean vaccine available prevent transmission hbv cure patients become chronically infected virus expected vaccine becomes widely available incidence hbv decrease existing therapies treating patients infected hbv include drugs epivirhbv form lamivudine sold glaxosmithkline introna form interferon alpha b sold schering plough epivirhbv orallyadministered drug prevents virus replicating patients introna injectable drug provide reduction amount virus blood patients often associated side effects believe fda approves adefovir dipivoxil epivirhbv would significant competition course certain adefovir dipivoxil approved treatment hbv determine adefovir dipivoxil would competitive epivirhbv see competition case hiv drug resistance serious problem drugs treat hbv available data date demonstrated resistancemutation associated adefovir dipivoxil hbv suggesting development resistance adefovir dipivoxil hbv patients may slow infrequent believe resistance profile adefovir dipivoxil could make adefovir dipivoxil important drug treating chronic hbv infection certain however resistance data may obtain much broader longer term phase iii clinical trials adefovir dipivoxil also show resistance characteristics described tenofovir df discontinued development mg doses adefovir dipivoxil treatment hiv due safety benefit concerns fda studies shown adefovir dipivoxil significantly effective hbv virus hiv virus allowing us use lower doses shown significant kidney toxicity clinical trials date limited clinical data mg dose adefovir dipivoxil obtained open label safety studies adefovir dipivoxil patients lamivudine resistant hbv either pre post liver transplant patients coinfected hivhbv studies demonstrated decrease hbv viral load similar seen mg dose phase ii studies certain broad long term studies adefovir dipivoxil mg mg doses demonstrate satisfaction fda regulatory agencies adefovir dipivoxil safe effective treatment chronic hbv hepatitis b common china southeast asian countries december received approval granted clinical trials permit initiate phase clinical trials china expect commence clinical trials limited regulatory expertise manufacturing marketing capacity china southeast asia therefore rely assistance third parties activities also difficult protect patents countries could adversely affected unable obtain adequate patent protection adefovir dipivoxil china southeast asia part approval commence phase clinical trials china adefovir dipivoxil granted class designation would give us years market exclusivity adefovir dipivoxil following regulatory approval china exclusive worldwide license patent rights related technology adefovir dipivoxil iocbrega would obligated pay net revenues sales adefovir dipivoxil iocbrega countries product patent protection see collaborative relationshipsiocbrega cidecin cidecin daptomycin injection investigational antibacterial compound developed cubist pharmaceuticals inc january entered agreement cubist granting us exclusive commercial rights cidecin european countries arrangement cubist responsible ongoing clinical trials product responsible european regulatory filings believe arrangement represents strategic opportunity us cidecin falls within therapeutic focus antiinfectives product approved could sold existing european sales marketing infrastructure laboratory tests suggested cidecin may effective rapidly killing grampositive bacteria including become resistant current therapies grampositive bacterial infections include complicated skin soft tissue infections bacteremia endocarditis infection valves heart complicated urinary tract infections pneumonia osteomyelitis infection bone bone marrow case hiv hbv resistance existing antibacterial therapy become significant problem treating infections laboratory tests confirmed clinical trials cidecin could useful drug treating serious infections assurance however results confirmed clinical trials cubist currently evaluating cidecin multiple phase iii trials treatment complicated skin soft tissue infection community acquired pneumonia cubist obtains data phase iii clinical trials show appropriate safety efficacy cidecin uses would file marketing authorization european union application approved would sell cidecin european sales marketing infrastructure march cubist announced preliminary data study study pivotal phase iii clinical trial evaluating cidecin complicated skin soft tissue infection according announcement primary endpoint trial demonstrating equivalency comparable agents achieved accurately predict outcome clinical trials trials conducted cubist successful may prevented obtaining regulatory approval cidecin europe may elect conduct additional trials together cubist pay portion costs associated trials cubist obligation conduct pay additional clinical trials cubist also evaluating cidecin phase iii clinical trial treatment complicated urinary tract infection openlabel phase ii clinical trial treatment bacteremia may evaluate cidecin treatment endocarditis infections agreement cubist require cubist continue complete trials cubist successfully completes phase iii clinical trials uses would seek regulatory approval uses territory would exclusive commercial rights indications territory predict outcome clinical trials cubist evaluate cidecin additional uses cubist also developing oral formulation daptomycin agreement cubist would give us exclusive commercial rights territory oral formulation daptomycin developed cubist required pay milestone payments cubist based upon certain development goals relating clinical development regulatory approval cidecin oral formulation daptomycin also required pay royalties cubist based upon sales cidecin oral formulation daptomycin see collaborative relationshipscubist oncology portfolio developing three investigational compounds oncology program one product candidates nx phase ii clinical trials two product candidates gs l gs preclinical development nx nx liposomal formulation lurtotecan anticancer compound developed glaxosmithkline glaxosmithkline granted us exclusive right develop commercialize nx see collaborative relationshipsglaxosmithklinenx prior granting us development commercialization rights glaxosmithkline conducted phase ii clinical trials nonliposomal lurtotecan treatment various forms cancer phase ii clinical trials showed lurtotecan anticancer activity believe glaxosmithkline continue pursuing development nonliposomal lurtotecan convinced phase ii clinical trials showed sufficient treatment benefits safe doses compared available anticancer agents entered development commercialization relationship glaxosmithkline believe delivering lurtotecan liposome may able increase treatment benefits lurtotecan give patients doses safe effective convenient lurtotecan class compounds called camptothecins compounds work disrupting cell 's ability use topoisomerase enzyme required cells replicate studies show ability compounds kill stop spread cancer cells directly related length time cancer cells exposed compound believe formulating lurtotecan liposome may able increase time exposure treatment benefits completed three phase single agent clinical trials evaluated different doses treatment schedules nx studies involved patients established maximum tolerated dose nx hematological toxicity dose limiting factor also observed antitumor biological activity seven difficult treat patients certain antitumor activity related nx since trials designed evaluate efficacy one additional phase single agent trial ongoing nx also evaluated phase trials combination another cancer therapy based phase results commenced phase ii clinical program evaluating nx treating patients ovarian cancer november two ovarian trials initiated one patients failed firstline chemotherapy one patients resistant topotecan addition initiated separate phase ii clinical trial december evaluate nx treatment patients smallcell lung cancer failure initial therapy also expect evaluate nx cancer types accurately predict outcome clinical trials required pay milestone payments glaxosmithkline achieve certain development goals related clinical development regulatory approval nx required pay royalties payments glaxosmithkline based upon sales nx see collaborative relationshipsglaxosmithklinenx gs l gs l also liposomal formulation compound developed glaxosmithkline treatment cancer acquired exclusive worldwide rights develop commercialize compound glaxosmithkline december prior acquiring rights glaxosmithkline discontinued development compound phase clinical trials case nx hope delivering compound using proprietary liposomal technology able improve safety efficacy profile compound investigational compound part class compounds known thymidilate synthase inhibitors ts inhibitors ts inhibitors act preventing production thymidilate synthase enzyme enzyme necessary cell growth enzyme expressed significantly higher levels tumor cells healthy cells making appropriate target cancer therapy ts inhibitors approved regulatory agencies used treating colorectal breast cancer preclinical studies date indicate liposomal formulation compound associated significant tumor growth inhibition may improve safety profile compound preclinical studies successful plan begin phase human clinical trials gs l certain preclinical studies successful even preclinical studies successful certain able submit application begin clinical testing commenced clinical trials would successful required pay milestone payments glaxosmithkline achieve certain development goals relating clinical development regulatory approval gs l also required pay royalties glaxosmithkline based upon sales gs l see collaborative relationshipsglaxosmithklinegs l gs also december acquired exclusive worldwide rights gs 'thioarac southern research institute sri evaluating gs preclinical studies potential treatment cancer gs class compounds called nucleoside analogs believed nucleoside analogues inhibit tumor cell growth preventing replication dna fdaapproved drugs class used treat acute chronic leukemias pancreatic nonsmall cell lung cancer gs demonstrated anticancer activity solid tumors preclinical studies conducted sri gilead certain preclinical studies successful required pay milestone payments sri achieve certain development goals relating clinical development regulatory approval gs also required pay royalties sri based upon sales gs see collaborative relationships southern research institute science research scientists foster city san dimas california boulder colorado engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs therapeutic focus areas infectious diseases cancer nucleotide analogues scientists working proprietary nucleotide analogues develop treatments viral infections compounds treat viral infections interfering activity certain enzymes necessary virus grow example vistide nucleotide analogue cytosine inhibits activity enzyme cytomegalovirus essential virus spread tenofovir df adefovir dipivoxil nucleotide analogues work inhibiting activity reverse transcriptase enzyme necessary replication hiv virus tenofovir df hbv virus adefovir dipivoxil viruses seeking treat using nucleotide analogues include herpes pox viruses also evaluating several nucleotide analogues animals activity cancer believe small molecule nucleotide analogues offer advantages therapeutics advantages include molecules demonstrated ability work infected uninfected cells could enable us develop drugs treat patient infected virus also prevent healthy person becoming infected first place drugs developed molecules shown treatment activity patient longer periods time available drugs could enable us develop drugs require less frequent dosing thus convenient patients given complexity drug development certain drug candidates develop science advantages even develop drug candidates advantages fda regulatory agencies could reject marketing approval drug candidates reasons including safety benefit concerns liposomes also scientists focused applying proprietary liposomal drug delivery technology develop safer effective convenient drugs liposomes submicroscopic structures made phospholipids basic components human cell walls hollow spheres drugs packed believe influence way compounds released distributed body placing liposomes turn improve safety treatment benefits compounds example developed ambisome incorporating amphotericin b liposome preclinical studies shown ambisome delivers amphotericin b manner results fewer side effects improved treatment benefits conventional amphotericin b including concentrating drug site infection extending time drug remains blood stream prolong therapeutic effect reducing kidney toxicity injection related reactions current strategy use liposomal technology compounds develop internally identify appropriate compounds developed third parties use technology compounds developed third parties appropriate technology include like amphotericin b proven therapeutic benefits suffer significant side effects suffer dosing administration problems believe use liposomal technology improve safety drugs maintaining even improving therapeutic benefits identified certain generic compounds compounds protected patents proprietary compounds owned third parties may benefit substantially liposomal technology begun formulation studies compounds addition discussed continue discuss collaborative relationships companies develop liposomal formulations compounds hiv protease inhibitors evaluating number small molecule compounds known protease inhibitors treatment hiv protease inhibitors act interfering activity protease enzyme like reverse transcriptase necessary replication hiv virus conducted number preclinical experiments compounds demonstrated potent antiviral activity scientists trying increase safety treatment benefits reduce resistance concerns compounds conducting preclinical development adenosine receptor regulators working national institute diabetes digestive kidney diseases national institutes health nih study compounds known adenosine receptor agonists antagonists treatment prevention neurodegenerative disorders disorders brain upper spine associated stroke also intend evaluate use compounds inflammatory allergic conditions nih researchers developed number compounds shown therapeutic benefits stroke drug discovery technologies technology call selex process used identify potential drug candidates process works identifying drug compounds known aptamers tend bind molecule causing disease aptamers tend bind disease molecules believe effective treating disease relatively low doses nx example aptamer identified selex process see collaborative relationshipseyetech marketing sales established us sales force therapeutic specialists began selling vistide result merger nexstar july also marketing subsidiaries united kingdom germany italy spain france portugal australia marketing operation greece sales professionals us europe australia promote sell ambisome daunoxome ambisome also sold fujisawa us copromote product canada pharmacia corporation promotes sells vistide countries outside us hoffmannla roche promotes sells tamiflu everywhere sold march entered promotion agreement virco group amended agreement february arrangement us therapeutic specialists promote virco 's hiv resistance monitoring services hivtreating physicians june us sales force currently consists approximately sales representatives five regional directors promote vistide physicians hospitals clinics healthcare providers treat aids patients ambisome infectious disease specialists hospitals home health care providers cancer specialists daunoxome cancer specialists hospitals us sales force supported managed carenational accounts team marketing sales support staff approximately people based headquarters foster city california international marketing subsidiaries headed general manager oversees operations markets served subsidiary currently approximately people located mainly europe including medical financial human resources personnel support international sales marketing operations subsidiaries also assist obtaining regulatory approvals countries located us sell vistide daunoxome wholesalers specialty distributors turn sell products physicians hospitals clinics pharmacies healthcare providers outside us agreements thirdparty distributors including distributors certain countries marketing operations promote sell distribute ambisome daunoxome international distribution agreements generally provide distributor exclusive right sell ambisome daunoxome particular country several countries specified period time tenofovir df approved treatment hiv larger sales force additional marketing resources would required us europe expand coverage healthcare professionals treating hiv patients current intention retain commercial rights adefovir dipivoxil hbv us europe sell marketing partners distributors asia rest world retain significant commercial rights adefovir dipivoxil hbv product approved would need increase sales force us europe use additional marketing resources sell product cidecin approved marketing europe believe given profile product target market existing sales force europe sufficient market cidecin vistide returnable original unopened container one year beyond expiration date damaged received customer customers may return ambisome daunoxome shelf life expired product damaged defective received customer ambisome approved shelf life months us months european countries daunoxome shelf life weeks us european countries additionally certain governmental agency customers entitled discounts required provide rebates state medicaid programs date returns rebates discounts material fujisawa establishes return policy ambisome north america hoffmannla roche establishes return policy tamiflu collaborative relationships part business strategy establish collaborations companies assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring companies products rights products technologies complementary business existing collaborative relationships follows hoffmannla roche september entered collaboration agreement hoffmannla roche develop commercialize therapies treat prevent flu agreement granted hoffmannla roche exclusive worldwide rights proprietary influenza neuraminidase inhibitors including tamiflu october fda approved tamiflu marketing november hoffmannla roche began selling tamiflu december received license fees milestone payments hoffmannla roche totaling million relating execution agreement regulatory filings approvals tamiflu hoffmannla roche also funded research development costs tamiflu including reimbursement us million period january december addition agreement hoffmannla roche responsible pricing promoting selling tamiflu worldwide basis hoffmannla roche pays us percentage net revenues sales tamiflu certain circumstances amount hoffmannla roche pays us may reduced example cost materials use manufacture tamiflu increases receive payments recognize revenue hoffmannla roche quarter following quarter sales made hoffmannla roche make milestone payments us tamiflu approved europe agreement hoffmanla roche terminates countrybycountry basis later expiration patent coverage tamiflu ten years first commercial sale hoffmannla roche right terminate agreement entirety countrybycountry basis prior expiration time upon months notice fujisawa entered agreement fujisawa providing exclusive right promote sell ambisome countries except us canada fujisawa exclusive right promote sell ambisome canada right copromote ambisome fujisawa us fujisawa primary responsibility promoting selling ambisome receive approximately net revenues sales ambisome us copromotion efforts receive payments recognize revenue fujisawa month following month fujisawa 's sales made would required pay fujisawa revenues connection sales ambisome significant asian markets including japan korea taiwan china india manufacture ambisome sales fujisawa purchases ambisome us sale us price equal cost manufacture product sale canada cost plus specified percentage agreement fujisawa terminates last patent covering ambisome us japan expires iocbrega entered agreements iocbrega relating nucleotide compounds discovered institutions december paid iocbrega million reduce royalties payable upon sales tenofovir df adefovir dipivoxil royalty rate agreements amendments agreements received iocbrega exclusive right manufacture use sell nucleotide compounds covered agreements countries patent protection required pay iocbrega net revenues generated sales tenofovir df adefovir dipivoxil net revenues generated sales vistide products containing compounds subject minimum royalty payments countries patent protection required pay royalties iocb rega sales tenofovir df adefovir dipivoxil required pay net revenues generated sales vistide products containing compounds currently making quarterly payments iocbrega based upon percentage sales vistide obligated pay additional amounts upon commercial sales adefovir dipivoxil tenofovir df amortize million payment made december estimated commercial lives tenofovir df adefovir dipivoxil reduce reported earnings products agreements iocbrega terminate countrybycountry basis later expiration patent coverage product licensed agreements ten years first commercial sale iocbrega may terminate licenses agreements particular product key markets make sales product within months regulatory approval countries cubist january entered agreement cubist giving us exclusive commercial rights european countries oral injectable formulations cubist 's investigational antibacterial compound daptomycin formulations include cidecin intravenous formulation daptomycin currently phase iii clinical trials treatment bacterial infections agreement cubist required complete ongoing clinical trials cidecin responsible regulatory filings products territory cidecin approved marketing territory responsible marketing cidecin territory paid upfront fee cubist million time signed agreement may required make additional payments cubist million certain goals related clinical development regulatory approval cidecin oral formulation daptomycin achieved required pay cubist percentage revenues sales products territory cubist desires grant commercial rights oral injectable daptomycinrelated product certain countries including country joins eu cubist must offer us commercial rights priority basis cubist obligated continue preclinical development oral formulation daptomycin would obligation pursue clinical development formulation appropriate agreement expires country country basis respect product developed upon later ten years first commercial sale product country date patent coverage product glaxosmithklinenx may entered agreements glaxosmithkline giving us rights glaxosmithkline 's proprietary compound lurtotecan granting glaxosmithkline rights use selex process identify aptamers therapeutic uses december glaxosmithkline waived right participate commercialization nx rights royalties based sales nx exchange agreement increase milestone payments upon marketing approvals nx agreement relating lurtotecan developing nx liposomal formulation lurtotecan agreement provides exclusive right develop commercialize nx may required make one time milestone payments glaxosmithkline achieve certain goals related clinical development regulatory approval nx pharmacia corporation august entered agreement pharmacia corporation relating vistide agreement received million signing million upon approval vistide marketing europe addition agreement pharmacia corporation exclusive right market sell vistide countries outside us right first negotiation competitive products responsible maintaining patents cidofovir required sell bulk cidofovir pharmacia corporation pharmacia corporation pay us percentage net sales vistide products developed collaboration agreement receive payments recognize revenue pharmacia corporation quarter following quarter sales made pharmacia corporation holds shares common stock purchased connection agreement pharmacia corporation may sell shares acquire additional shares stock without approval june agreement pharmacia corporation expires countrybycountry basis patent coverage vistide expires ten years first commercial sale vistide countries product covered patent addition pharmacia corporation may terminate agreement upon six months notice upon notice countrybycountry basis three months applying marketing approval competitive product glaxosmithklinegs l december entered agreement glaxosmithkline giving us rights gs l novel antitumor compound agreement exclusive worldwide right develop commercialize gs l indications malaria developing gs l liposome evaluating preclinical studies oncology paid upfront fee glaxosmithkline time signed agreement may required make payments glaxosmithkline achieve certain goals related clinical development regulatory approval gs l successfully commercialize product would required pay glaxosmithkline percentage net sales agreement expires country country basis respect product developed upon later ten years first commercial sale product country date patent coverage product southern research institute december entered agreement sri giving us rights gs novel antitumor compound agreement exclusive worldwide right develop commercialize gs indications evaluating compound preclinical studies oncology paid upfront fee sri time signed agreement may required make payments sri achieve certain goals related clinical development regulatory approval gs successfully commercialize product would required pay sri percentage net sales agreement expires country country basis respect product developed upon later ten years first commercial sale product country date patent coverage product sumitomo pharmaceuticals co ltd entered agreement sumitomo pharmaceuticals co ltd gave sumitomo exclusive right develop market ambisome japan sumitomo paid us million time entered agreement million march sumitomo made regulatory filing japan terms agreement sumitomo required make payment million us ambisome approved sale japan sumitimo required pay us percentage revenue generate sales ambisome ambisome approved japan would manufacture ambisome sale sumitomo japan price would charge sumitomo supply ambisome percentage revenues would required pay us would determined price ambisome japan agreement terminates later ten years sumitomo begins selling ambisome japan date last patent ambisome japan expires eyetech pharmaceuticals march entered agreement eyetech pharmaceuticals inc relating nx received million upfront licensing fee eyetech upon execution agreement terms agreement eyetech received exclusive right develop commercialize nx entitled additional cash payments eyetech million eyetech reaches certain nx development milestones product successfully commercialized eyetech pay us royalties worldwide sales product part transaction received fiveyear warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors required license agreement university technology corporation transferred warrant university technology corporation right acquire shares therefore currently hold warrant purchase shares addition agreed provide clinical supplies product eyetech initial oneyear period agreement expires upon later ten years first commercial sale product developed date last patent expires agreement virco group march entered agreement virco group relating virco 's hiv resistance monitoring services agreement help promote virco 's hiv resistance monitoring services virco pays us fixed fee promotion agreement terminate june proligo llc interest proligo llc company manufactures oligonucleotides also agreements proligo skw americas inc owner remaining proligo relating ownership operations funding proligo agreements contributed total million proligo fund operations late early funding obligations proligo skw americas right purchase ownership interest proligo day period beginning july amount would required pay interest purchased next three years skw americas obligated pay us approximately proligo agreed manufacture oligonucleotides us would pay amount equal manufacturing cost plus pre determined percentage proligo dissolve remaining assets distributed owners august unless owners proligo time decide extend term agreement relating manufacture supply oligonucleotides expires august glaxosmithklineselex time entered agreement glaxosmithkline relating nx also entered agreement giving glaxosmithkline nonexclusive right use selex technology five years identify aptamers glaxosmithkline would required pay us fee time enter additional agreement glaxosmithkline would required make payments us based achieving certain goals relating regulatory approval product develop based aptamer glaxosmithkline would required pay us percentage revenues may generate sales product develop based aptamer agreement terminates may except glaxosmithkline extend agreement additional one year periods case glaxosmithkline would required pay us appropriate fee glaxosmithkline terminate agreement earlier time days notice us somalogic inc november entered agreement somalogic inc company formed larry gold founder nexstar relating selex technology agreement gave somalogic exclusive right use selex technology make sell vitro diagnostic products diagnostic products used person animal assigned sold somalogic certain patents materials relating vitro diagnostics including robotic selex machines right use drug discovery technology subject agreement internally study diseases drug development clinical trial programs somalogic paid us first installment fee time entered agreement second final installment november agreement terminates later country country basis patent coverage drug discovery technology expires november international distribution agreements various agreements distributors europe asia south america middle east africa grant distributors exclusive right sell ambisome cases daunoxome particular country countries specified period time agreements also provide collaborative efforts us distributor obtaining regulatory approval product particular country marketing product country agreements establish price distributor must pay product require us deliver quantities product ordered distributor academic consulting relationships supplement research development efforts part regular business enter arrangements universities medical research institutions arrangements often provide us rights patents patent applications technology owned institutions return payments fees relating use rights university technology corporation ongoing collaborative arrangement relating selex technology university technology corporation technology holding company university colorado boulder arrangement university colorado boulder given us present future rights inventions covered patents patent applications selex technology improvements selex technology makes discovers oligonucleotides molecules makes using selex technology results certain research computer software related selex technology required pay university colorado boulder revenues generate sales selexderived products amounts receive third party based upon sales third parties selexderived products payments receive third parties result certain arrangements third parties develop sell selexderived products manufacturing ambisome daunoxome manufacture ambisome daunoxome commercial quantities two separate adjacent facilities san dimas california medicines control agency united kingdom approved facilities manufacture ambisome daunoxome commercial use fda approved facilities manufacture ambisome one facilities manufacture daunoxome distribution us import ambisome daunoxome european union manufacturing facility dublin ireland perform quality control testing final labeling packaging european union elsewhere use commercially available materials equipment manufacture products currently obtain amphotericin b daunorubicin hcl cholesterol use manufacture ambisome daunoxome single approved suppliers ambisome currently freeze dried san dimas manufacturing facility sold freezedried product given demands projections growth ambisome use currently using two different third parties freeze dry product evaluating feasibility installing additional freeze drying capacity san dimas unable locate appropriate third parties install validate additional freeze drying capacity san dimas ability increase ambisome sales would diminished manufacturing liposomal products particularly complex process new liposomal product develop require unique complex variations manufacturing process antiviral products hire third parties manufacture antiviral drugs clinical commercial purposes including vistide adefovir dipivoxil tablets tenofovir df tablets hoffmannla roche manufactures tamiflu commercialscale manufacturing facilities antiviral products qualified fda 's current good manufacturing practices current plans establish facilities using third parties certain perform obligations effectively timely basis third parties perform effectively timely clinical trials regulatory filings could delayed could unable deliver products customers timely basis would adversely affect operating results one supplier approved fda emea manufacture cidofovir used vistide single fda approved supplier final drug product submitted information second cidofovir supplier assure supplies manufacture active ingredient tenofovir df small quantities facilities larger quantities two contract manufacturers final tenofovir df adefovir tablets used clinical trials manufactured two contract manufacturing sites manufacturing sites use interrupted reason ability complete clinical trials ship products would impaired would adversely affect us antiviral products particular need develop additional manufacturing capabilities establish additional third party suppliers order manufacture sufficient quantities product candidates complete clinical trials manufacture sufficient quantities candidates approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms antiviral products ability conduct largescale clinical trials meet customer demand commercial products would adversely affected believe technology use manufacture products compounds proprietary antiviral products disclosed necessary aspects technology contract manufacturers enable manufacture products compounds us agreements manufacturers intended restrict using revealing technology certain manufacturers comply restrictions addition manufacturers could develop technology related work perform us may need manufacture products compounds could required enter agreement manufacturer wanted use technology allow another manufacturer use technology manufacturer could refuse allow us use technology could demand terms use technology acceptable believe compliance material environmental regulations related manufacture products patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection us internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates us europe primary patents patents may issue pending applications cover compounds marketed products product candidates us patent expiration european patent expiration products ambisome tamiflu vistide daunoxome product candidates tenofovir df adefovir dipivoxil nx nx gs l gs cidecin na applications patents pending patents applications issue would patent protection dates indicated would instead rely patents expire earlier example patent tenofovir df issue patents expire provide protection method use patents general method use patents provide level protection composition matter patents commercial rights cidecin united states patents covering vistide tenofovir df adefovir dipivoxil lurtotecan active ingredient nx cidecin gs l gs held third parties acquired exclusive rights patents agreements parties see collaborative relationships patents cover active ingredients ambisome daunoxome instead hold patents liposomal formulations compounds also protect formulations trade secrets patent filings covering adefovir dipivoxil china certain asian countries although applications pending various asian countries including china relate specific forms formulations adefovir dipivoxil asia major market hbv therapies may obtain patents compounds many years obtain marketing approval limits time prevent companies developing compounds therefore reduces value product however apply patent term extensions example extensions patents vistide applied granted us number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third party allowing us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license could adversely affected patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation reexamination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection addition pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products developing also us patent applications generally maintained secrecy patents issued certain inventor technologies covered pending patent applications first file patent applications inventions also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements would adequate remedies breach trade secrets otherwise become known independently discovered competitors research development agreements inventions discovered certain cases become jointly owned us corporate partner cases become exclusive property one us difficult determine owns particular invention disputes could arise regarding inventions competition products development programs target number diseases conditions including fungal infections viral infections cancer many commercially available products diseases large number companies institutions spending considerable amounts money resources develop additional products treat diseases current products compete available products based primarily product performance safety tolerability acceptance doctors patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability various modes dosing products market future also compete products offered competitors competitors introduce data shows improved characteristics products improve increase marketing efforts simply lower price products sales products could decrease also certain products develop future compare favorably products offered competitors existing future products compare favorably new products developed competitors ability competitive also depends upon ability attract retain qualified personnel obtain patent protection otherwise develop proprietary products processes secure sufficient capital resources substantial period takes develop product markets ambisome approved first line therapy competes traditional amphotericin b made bristolmyers squibb company numerous generic manufacturers expect face significant competition new antifungal products including caspofungin product developed merck received marketing approval january voriconazole developed pfizer inc phizer filed application marketing approval voriconazole also number lipidbased amphotericin b products approved us throughout europe including abelcet sold elan corporation amphotec sold intermune pharmaceuticals inc products compete ambisome primary secondary therapy offered prices less ambisome 's price tamiflu competes relenza antiflu drug sold glaxosmithkline relenza neuraminidase inhibitor delivered orallyinhaled dry powder addition johnson johnson biocryst developing neuraminidase inhibitor antiflu drug represent significant competition fda approves drug may administered oncedaily pill opposed tamiflu must taken twice daily certain tamiflu compare favorably drug based performance price length dosing side effects criteria johnson johnson advanced clinical trials compound unclear product may market vistide competes number drugs also treat cmv retinitis drugs include ganciclovir drug sold intravenous oral formulations hoffman laroche ocular implant bausch lomb incorporated foscarnet intravenous drug sold astrazeneca formivirsen drug injected directly eye sold cibavision approved tenofovir df face substantial competition number drugs treat hiv infection aids currently sold advanced stages clinical development including products currently sold us among companies significant competitors hiv aids market glaxosmithkline bristolmyers squibb hoffmannla roche pfizer merck dupont pharma lamivudine drug developed glaxosmithkline collaboration biochem pharma lamivudine sold us china several countries shown effective treating patients hbv adefovir dipivoxil approved treat hbv lamivudine significant competition drugs approved awaiting approval treatment kaposi 's sarcoma us europe including one sold liposomal formulation drugs compete expected compete daunoxome number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together biopharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs anticipate face increased competition future competitors introduce new products market new technologies become available determine existing products new products competitors develop effective effectively marketed sold develop competitive products could render technology products obsolete noncompetitive recover money resources used develop products government regulation operations activities subject extensive regulation numerous government authorities us countries us drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion products result regulations product development product approval process expensive time consuming fda must approve drug sold us general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug 's potential safety benefits submit data fda investigational new drug application ind seeking approval test compound humans clinical trials fda accepts investigational new drug application study drug human clinical trials determine drug safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug given small number healthy human subjects patients test safety dose tolerance pharmacokinetics metabolism distribution excretion phase ii drug given limited patient population determine effect drug treating disease best dose drug possible side effects safety risks drug phase iii compound appears effective safe phase ii clinical trials phase iii clinical trials commenced confirm results phase iii clinical trials longterm involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug uncommon drug appears promising phase ii clinical trials fail rigorous reliable phase iii clinical trials fda approval process believe data phase iii clinical trials show adequate level safety effectiveness file new drug application nda fda seeking approval sell drug particular use fda review new drug application often hold public hearing independent advisory committee expert advisors asks additional questions regarding drug committee makes recommendation fda binding fda generally followed fda fda agrees compound required level safety effectiveness particular use allow us sell drug us use unusual however fda reject application believes drug safe enough effective enough believe data submitted reliable conclusive point process development drug could stopped number reasons including safety concerns lack treatment benefit certain phase phase ii phase iii clinical trials conducting including tenofovir df hiv adefovir dipivoxil chronic hbv conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require us complete additional testing provide additional data information improve manufacturing processes procedures facilities require extensive postmarketing testing surveillance monitor safety benefits product candidates determine new drug application contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug approvals also withdrawn fda believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug manufacturing facilities drug sell including companies manufacture drugs us well must approved fda subject periodic inspections fda foreign establishments manufacture products sold us must also approved fda subject periodic regulatory inspection manufacturing facilities located california including san dimas facility foster city facility also must licensed state california compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs may designated fast track products fda may eligible priority six month review accelerated approval drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug tenofovir df hiv qualified fast track product may eligible accelerated approval determined would seek fast track status products qualified impact status timing likelihood approval potential products competitors also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds research development activities eliminate risk accidental contamination injury materials misuse accidents involving materials could lead significant litigation fines penalties drugs also subject extensive regulation outside us european union centralized approval procedure authorizes marketing product countries european union includes major countries europe procedure used decentralized system approval one country european union used obtain approval another country european union simplified application process approval centralized procedure pricing reimbursement approvals also required countries vistide approved european union centralized procedure tamiflu tenofovir df reviewed centralized procedure neither drug approved europe pricing reimbursement insurance companies health maintenance organizations hmos thirdparty payors governments seek limit amount charge drugs example certain foreign markets pricing negotiations often required obtain approval product us expect continue number federal state proposals implement drug price control addition managed care organizations becoming common us continue seek lower drug prices announcement proposals efforts cause stock price lower proposals adopted revenues would decrease ability sell drugs also depends availability reimbursement governments private insurance companies governments insurance companies often demand rebates predetermined discounts list prices expect products developing particularly aids indications subject reimbursement issues certain products obtain regulatory approval reimbursed government insurance companies regulatory approval prices generally required foreign countries particular certain countries condition approval product agreement seller sell product certain price country past required price reductions connection product approval certain regulatory authorities future establish lower prices regulatory action reducing price products one country practical effect requiring us reduce prices countries employees february fulltime employees believe good relations employees risk factors evaluating business carefully consider following risks addition information report following risks could materially adversely affect business operating results financial condition significant reduction ambisome sales would significantly reduce operating income could require us scale back manufacturing operations reduce sales force ambisome sales years ended december approximately million million total revenues expect revenues sales ambisome continue constitute substantial majority total product revenues least accordingly foreseeable future expect continue rely sales ambisome support existing manufacturing sales infrastructure provide operating income offset significant portion administrative research development expenditures significant reduction sales ambisome whether result introduction competitive products otherwise would hurt business would scale back manufacturing operations reduce sales force several products market compete ambisome generally priced lower ambisome expect face significant competition new antifungal products including caspofungin product developed merck received marketing approval january voriconazole developed pfizer inc pfizer filed application marketing approval voriconazole tamiflu new drug may gain significant market acceptance people become infected flu use overthecounter drugs treat flu symptoms rely immune system fight infection tamiflu new class prescription drugs designed prevent treat flu patients may reluctant visit physician seek prescription drug flu physicians may reluctant prescribe flu drug government reimbursers private insurance companies may refuse pay antiflu drug order tamiflu successful marketing partner hoffmannla roche need increase awareness acceptance new approach preventing treating flu flu season first flu season tamiflu commercially available date incidence flu flu season low early determine tamiflu achieve significant market acceptance history losses expect operate loss foreseeable future may never profitable never profitable fullyear basis may never become profitable december accumulated deficit approximately million losses resulted principally expenses associated research development programs lesser extent sales general administrative expenses product sales royalty revenues derived sales ambisome vistide daunoxome royalty arrangements related tamiflu ambisome vistide develop drugs treat hiv aids related conditions therefore changes regulatory commercial environment hiv aids therapies could harm business several products products development address hiv aids related conditions products include vistide cmv retinitis tenofovir df hiv aids daunoxome hivassociated kaposi 's sarcoma develop products based upon current policy current marketplace hiv aids therapies well prediction future policy future marketplace therapies business subject substantial risk policies markets change quickly unpredictably ways could impair ability obtain regulatory approval commercial acceptance products operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis achieve continued compliance could delay commercialization products products develop sell must approved subject extensive regulation fda comparable agencies countries continuing clinical trials ambisome currently approved additional uses also conducting clinical trials three products tenofovir df adefovir dipivoxil nx anticipate conduct variety clinical trials file marketing approval additional products next several years products may fail receive marketing approval timely basis also certain file nda tenofovir df midyear unexpected results ongoing clinical trials unexpected requests fda additional data could delay prevent filing addition tenofovir df may granted priority review fda means nda would reviewed within months submission addition products may receive marketing approvals place limitations uses failures delays limitations well regulatory changes actions recalls could delay commercialization products adversely affect results operations addition even products marketed products manufacturers subject continual review later discovery previously unknown problems products manufacturing production thirdparty manufacturers may result restrictions products manufacture products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution results clinical trials approval products uncertain may delayed prohibited selling products number potential products reached development stage potential products include tenofovir df adefovir dipivoxil nx gs l gs required demonstrate safety effectiveness products develop intended use extensive preclinical studies clinical trials order obtain regulatory approval products results preclinical early clinical studies always accurately predict results later largescale clinical trials several reasons including preliminary results may indicative effectiveness clinical trials may achieve desired result clinical trials may reveal unduly harmful side effects may show drugs less effective drugs delivery systems desired indications even successfully completed largescale clinical trials may result marketable products several reasons including potential products shown safe effective regulatory authorities disagree results design studies trials potential products difficult develop commercially viable products november fda advisory committee recommended approval application approve mg dose adefovir dipivoxil treat hiv kidney toxicity associated mg dose well desire additional data major concerns committee following recommendation informed fda would approve application unless obtained additional data satisfied concerns raised committee based discussions terminated development adefovir dipivoxil treatment aids using mg doses adefovir dipivoxil phase iii clinical trials adefovir dipivoxil hbv believe lower doses result kidney toxicity experienced mg adefovir dipivoxil effective treating hbv lower doses certain however lower doses safe enough sufficient treatment benefits receive fda approval tenofovir df class drugs adefovir dipivoxil yet observed kidney toxicity clinical trials tenofovir df kidney toxicity clinical trials adefovir dipivoxil hiv arise later stages clinical trials certain similar toxicity issues arise later clinical trials tenofovir df number companies industry suffered similar setbacks advanced clinical trials despite promising results earlier trials end may unable develop additional marketable products delays patient enrollment clinical trials could increase costs delay regulatory approvals rate completion clinical trials depend rate patient enrollment substantial competition enroll patients clinical trials drugs development competition delayed clinical trials past addition recent improvements existing drug therapy particularly hiv hbv certain cancers may make difficult us enroll patients clinical trials patient population may choose enroll clinical trials sponsored companies choose alternative therapies delays planned patient enrollment result increased development costs delays regulatory approvals product development efforts may yield marketable products due results studies trials failure achieve regulatory approvals market acceptance proprietary rights others manufacturing issues success depends ability successfully develop obtain regulatory approval market new pharmaceutical products significant portion research conduct involve new unproven technologies development product requires substantial technical financial human resources even product successfully completed potential products may appear promising various stages development yet fail reach market number reasons including lack sufficient treatment benefit unacceptable toxicity preclinical studies clinical trials failure receive necessary regulatory approvals existence proprietary rights third parties inability develop manufacturing methods efficient costeffective capable meeting stringent regulatory standards product sales occur outside us currency fluctuations may impair financial results significant majority sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition hedge respect foreign accounts receivable hedge exposure impact fluctuating foreign exchange rates forecasted sales foreign currency fluctuations continue affect future results product development expenses cause operating expenses fluctuate quarter quarter clinical trials required regulatory approval products extremely expensive difficult accurately predict control amount timing expenses quarter quarter uneven unexpected spending programs causes operating results fluctuate quarter quarter depend relationships companies research funding clinical development sales marketing performance revenues failure maintain relationships would negatively impact business rely number significant collaborative relationships major pharmaceutical companies research funding clinical development andor sales marketing performance include collaborations fujisawa healthcare glaxosmithkline hoffmannla roche pharmacia corporation eyetech pharmaceuticals inc sumitomo pharmaceuticals co inc also rely international distributors sales ambisome certain countries addition recently entered collaboration agreement cubist pharmaceuticals inc commercialize cubist 's antibacterial drug cidecin several european countries following regulatory approval agreement cubist responsible ongoing clinical development cidecin accordingly control rely cubist 's clinical trials regulatory filings cidecin ongoing clinical trials support regulatory approval cubist required conduct additional clinical trials may choose conduct trials expense reliance collaborative relationships poses number risks including able control whether corporate partners devote sufficient resources programs products disputes may arise future respect ownership rights technology developed corporate partners disagreements corporate partners could lead delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose devote fewer resources marketing products products development risks related ability distributors corporate partners pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenue existing products including tamiflu ambisome could decline rights market ambisome us canada limited agreement fujisawa failure fujisawa effectively market ambisome may reduce revenues rights market ambisome us canada subject agreement fujisawa terms agreement sole marketing rights ambisome countries except us canada must pay royalties connection sales significant asian markets including japan copromote ambisome fujisawa us manufacture ambisome sale us canada sell ambisome fujisawa cost us cost plus specified percentage canada fujisawa collects revenues ambisome sales us pays us approximately net sales success ambisome us dependent primarily efforts fujisawa canada success ambisome depend entirely fujisawa fujisawa fails efforts potential revenues sales ambisome may substantially reduced failure hoffmannla roche effectively market tamiflu would reduce potential revenues hoffmannla roche sole responsibility promoting selling tamiflu worldwide basis control activities therefore relying efforts hoffmannla roche revenues receive sale tamiflu hoffmann la roche dedicate sufficient resources promotion tamiflu hoffmannla roche fails marketing efforts royalties receive sale tamiflu would decrease would adversely affected inability establish future successful collaborative relationships may impair financial results may seek future collaborative relationships corporate partners fund research development expenses develop commercialize potential products anticipate revenues collaborative agreements continue affected existing agreements well timing drug development programs corporate partners may able negotiate acceptable collaborative arrangements future arrangements negotiate may successful fail establish additional collaborative relationships required undertake research development marketing manufacturing proposed products expense discontinue reduce activities existing products products development may accepted physicians insurers patients many products development approved marketing would established market ability products achieve sustain market acceptance depend receipt scope regulatory approvals whether government authorities managed care organizations adequately reimburse patients use products addition need convince medical patient advocacy community effectiveness products treating disease safety products administered patients advantages products competitive products physicians patients patient advocates payors medical community general may accept use products may develop products accepted results operations suffer many companies targeting diseases conditions competitive products companies could significantly reduce market acceptance products products development programs target number diseases conditions including viral infections fungal infections bacterial infections cancer many commercially available products diseases certain products wellestablished therapies generated substantial sales addition large number companies institutions conducting wellfunded research development activities directed developing treatments diseases products currently market development competitors could make technology products obsolete noncompetitive expect competition treatment diseases increase future new products enter market advanced technologies become available also competing license acquire technology companies competitors potential competitors substantially greater resources resources include superior product development capabilities financial scientific manufacturing marketing managerial human resources competitors may achieve superior patent protection obtain key technology receive regulatory approval achieve product commercialization earlier us significantly greater resources marketing organizations large pharmaceutical companies could hinder ability compete successfully products compete products may develop likely compete products companies currently extensive wellfunded marketing sales operations companies capable devoting significantly greater resources marketing efforts marketing sales efforts may compete successfully efforts companies existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payor reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement government authorities thirdparty payors increasingly challenging price medical products services particularly innovative new products therapies resulted lower average sales prices example majority sales ambisome vistide daunoxome subject reimbursement government agencies resulting significant discounts list price rebate obligations tamiflu approved sale europe success also depend largely obtaining government reimbursement europe many european countries including united kingdom france patients reluctant pay prescription drugs pocket also expect success products development particularly europe depend ability obtain reimbursement even reimbursement available reimbursement policies may adversely affect ability sell products profitable basis addition many international markets governments control prices prescription pharmaceuticals markets marketing approval received pricing negotiation take another six twelve months longer product sales attempts gain market share introductory pricing programs competitors could require us lower prices countries could adversely affect results operations may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others rights us foreign issued patents filed continue file patent applications us abroad relating technologies risk however patents may issue applications patents sufficient protect technology patent applications us generally confidential patent granted result may know competitors filed patent applications technology covered pending applications also certain first invent technology subject patent applications gs cidecin protected method use patents generally provide level protection composition matter patents competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents patent filings covering adefovir dipivoxil china certain asian countries although applications pending various asian countries including china relate various forms formulations adefovir dipivoxil asia major market hbv therapies one potential indications adefovir dipivoxil may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale commercial value product may limited addition patents may provide adequate protection certain countries africa asia including china competitors may file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even successful success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties certain would able obtain alternative technologies required license even obtain technologies licenses certain terms would reasonable fail obtain licenses alternative technologies may unable develop products example may decide use assay method drug screening programs ict pharmaceuticals patents may cover parts program ict pharmaceuticals offered us nonexclusive license patents part industrywide licensing program determined need patents program would need obtain license develop acquire alternative technologies program certain would able obtain license reasonable terms alternative technologies could serve needs future drug development addition ohio state university holds patent may need develop commercialize nx ohio state university offered us nonexclusive license patent entered option ohio state university enter license elect enter agreement ohio state university option required pay fees product royalty nx addition use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors manufacturing problems could delay product shipments regulatory approvals vistide adefovir dipivoxil tenofovir df rely third parties manufacture bulk drug substance final drug product clinical commercial purposes hoffmannla roche responsible manufacturing tamiflu encounter problems process revenues sales tamiflu could decrease depend third parties perform obligations effectively timely basis third parties fail perform required clinical trials submission products regulatory approval may delayed delays could impair ability deliver commercial products timely basis could impair competitive position manufacture ambisome daunoxome facilities san dimas california formulation manufacturing facilities san dimas california although manufacturing facility ireland performs certain quality control testing labeling packaging use third parties alternate contract suppliers fill freeze dry certain batches product event natural disaster including earthquake equipment failure strike difficulty may unable replace manufacturing capacity timely manner would unable manufacture ambisome daunoxome meet market needs may able obtain materials necessary manufacture products many materials utilize operations made one facility example depend single suppliers high quality amphotericin b daunorubicin hcl high quality cholesterol used manufacture one liposome products suppliers key components materials must named new drug application filed fda product significant delays occur qualification new supplier required supplies suppliers interrupted reason could unable ship ambisome vistide daunoxome supply products development clinical trials limited experience manufacturing products may able develop adequate manufacturing capacity potential products need develop production technologies use larger scale order conduct clinical trials produce products commercial sale acceptable cost certain able implement developments successfully manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations fda 's current good manufacturing practices extensive regulations governing manufacturing processes stability testing recordkeeping quality standards addition manufacturing operations subject routine inspections regulatory agencies similar regulations effect countries business may give rise product liability claims covered insurance indemnity agreements testing manufacturing marketing use ambisome vistide daunoxome well products development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others successful product liability claim us could require us pay substantial amounts could impair financial condition ability clinically test market products additionally required governmental regulations test products even sold used patients result tests may required may determine recall products already market subsequent testing product recalls may increase potential exposure product liability claims use hazardous materials chemicals viruses radioactive compounds exposes us potential liabilities research development involves controlled use hazardous materials chemicals viruses various radioactive compounds although believe safety procedures handling disposing materials comply standards prescribed state federal regulations completely eliminate risk accidental contamination injury materials event accident could held liable significant damages fines item properties corporate headquarters including principal executive offices certain research facilities located foster city california location lease approximately square feet space eight proximately located buildings one subleases covering square feet space group buildings expires december renewal options remaining leases expire march september option renew leases two additional fiveyear periods boulder colorado lease facility approximately square feet office space use administrative offices lease expires february option renew two additional fiveyear periods also lease approximately square feet space use research laboratories administrative offices lease expires october option renew lease two successive fiveyear periods also occupy facilities san dimas california leases expire may november two fiveyear renewal options facilities cover square feet space house research development activities manufacturing certain administrative functions also leased warehouse facility adjacent facilities use product distribution administrative functions facility square feet space lease expires april two additional fiveyear extensions addition lease approximately square feet space sales marketing regulatory finance information technology human resource operations europe australia including prepaid year lease square foot manufacturing distribution facility ireland leases various expiration dates item legal proceedings august entered settlement elan corporation successor liposome company inc agreed dismiss legal proceedings involving patents related liposomal formulation amphotericin b settlement agreement elan agreed sue us connection worldwide production sales ambisome gave us rights use patents terms settlement agreement required make payments based ambisome sales next several years also party various legal actions arose ordinary course business believe legal actions significant impact business item submission matters vote securities holders special meeting stockholders held february redwood city california shares gilead common stock entitled vote meeting shares represented meeting person proxy constituting quorum stockholders approved amendment gilead 's certificate incorporation increase authorized number shares common stock shares shares votes cast proposal votes cast abstentions broker nonvotes part ii item market registrant 's common stock related stockholder matters common stock traded nasdaq stock market symbol gild following table sets forth periods indicated high low intraday sale prices per share common stock nasdaq stock market prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february company implemented twoforone stock split form stock dividend share per share amounts periods presented restated reflect split february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception anticipate paying foreseeable future december gilead issued million convertible subordinated notes due december private offering jp morgan co lehman brothers morgan stanley dean whitter resold notes private institutional investors item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data years ended december consolidated statement operations data total revenues total costs expenses loss operations loss cumulative effect change accounting principle cumulative effect change accounting principle net loss basic diluted loss per common share loss cumulative effect change accounting principle cumulative effect change accounting principle net loss common shares used calculate basic diluted net loss per common share december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible subordinated debt accumulated deficit total stockholders ' equity periods prior year ended december restated reflect merger nexstar pharmaceuticals inc july accounted pooling interests gilead adopted staff accounting bulletin revenue recognition financial statements fourth quarter effect change recorded cumulative effect change accounting principle effective first quarter february company implemented twoforone stock split form stock dividend share per share amounts periods presented restated reflect split cash dividends declared paid company 's common stock item management 's discussion analysis financial condition results operations overview gilead sciences inc gilead incorporated delaware june independent biopharmaceutical company seeks provide accelerated solutions patients people care discover develop manufacture commercialize proprietary therapeutics challenging infectious diseases viral fungal bacterial diseases cancer gilead also expertise liposomal drug delivery technology currently market ambisomeregistered trademark amphotericin b liposome injection antifungal agent daunoxomeregistered trademark daunorubicin citrate liposome injection drug approved treatment kaposi 's sarcoma vistideregistered trademark cidofovir injection treatment cytomegalovirus cmv retinitis hoffmannla roche inc markets tamiflutm oseltamivir phosphate treatment influenza collaborative agreement gilead addition developing products treat diseases caused human immunodeficiency virus hiv hepatitis b virus hbv bacterial infections cancer february gilead completed twoforone stock split effected form stock dividend stockholders record february accordingly share per share amounts periods presented restated retroactively reflect split year ended december gilead adopted securities exchange commission 's staff accounting bulletin revenue recognition financial statements resulting cumulative effect change accounting principle july gilead entered business combination nexstar pharmaceuticals inc nexstar business combination accounted pooling interests historical consolidated financial statements gilead periods prior business combination restated include financial position results operations cash flows nexstar certain prior period amounts reclassified conform current presentation forwardlooking statements risk factors following discussion contains forwardlooking statements involve risks uncertainties gilead 's actual results could differ materially discussed forwardlooking statements factors could cause contribute differences include limited discussed section well caption business including risk factors part forwardlooking statements included document based information currently available gilead assume obligation update forwardlooking statements following discussion read conjunction consolidated financial statements notes included elsewhere report ambisome sales rely sales ambisome significant portion operating income lower priced products compete ambisome product recently approved compete ambisome products developed could compete ambisome future products achieve market acceptance products development become commercially available revenues sales ambisome would likely decrease resulting reduction operating income regulatory process us food drug administration fda foreign agencies could reject limit commercialization products number reasons including disagree results designs clinical trials believe products unacceptable efficacy toxicity tolerability believe products safely efficiently manufactured commercial basis agencies reject limit commercialization products financial results would adversely affected clinical trials required regulatory approval products extremely expensive difficult us accurately predict control amount timing expenses quarter quarter addition regulatory agencies could require us conduct additional unanticipated clinical trials products cost could substantial market acceptance products ability products achieve sustain market acceptance depend number factors including receipt scope regulatory approvals availability public private insurance reimbursement products safety efficacy tolerability cost products products compare competitive products products achieve sustain market acceptance results operations suffer tamiflu new class drugs represent new approach treating flu order tamiflu achieve market acceptance marketing partner hoffmannla roche inc must change attitudes toward treatment influenza collaborations depend collaborations development commercialization certain products revenue including collaboration hoffmannla roche inc sales tamiflu worldwide collaboration fujisawa healthcare inc fujisawa sales ambisome united states canada collaborations could fail number reasons including partners devote sufficient resources development commercialization marketing products disputes arise partners also seek additional collaborations collaborations fail unable establish additional collaborations financial results would adversely affected foreign currency fluctuations significant majority product sales denominated foreign currencies increases value us dollar foreign currencies past reduced future may reduce us dollar return sales negatively impact financial condition hedge exposure impact fluctuating foreign exchange rates forecasted sales hedge accounts receivable balances denominated foreign currencies minimizes exposure currency fluctuations date sale recorded date cash collected uncertain financial results expect financial results continue fluctuate quarter quarter fluctuations may substantial fluctuations caused many factors beyond control including risk factors listed never profitable fullyear basis may never achieve sustain profitability december accumulated deficit million results operations revenues total revenue million year million year million year included total revenue net product sales royalty income contract revenue including research development rd collaborations net product sales revenue million compared million million revenues primarily derived sales ambisome represented total product sales total product sales total product sales reported sales ambisome million increase ambisome sales million excluding impact decline foreign currencies relative us dollar sales ambisome would increased significant majority gilead 's product sales denominated foreign currencies hedge exposure impact fluctuating foreign exchange rates forecasted sales hedge accounts receivable balances denominated foreign currencies minimizes exposure currency fluctuations date sale recorded date cash collected sales ambisome million increase ambisome sales compared materially affected changes foreign currency rates gilead also recognized product sales revenue million sales daunoxome million sales vistide daunoxome sales million vistide sales million reported daunoxome sales million vistide sales million expect combined sales daunoxome vistide future decrease slightly compared levels reported royalty revenue million compared million million threeyear period significant source royalty revenue sales ambisome united states fujisawa copromotion arrangement gilead fourth quarter began recognizing royalty revenues fujisawa 's sales ambisome month following related product sales occur prior fourth quarter recognized royalty revenue month sales occurred royalty revenue fujisawa million compared million million amount represents royalties months fujisawa sales ambisome also reported royalty revenue million related sales tamiflu tamiflu orally administered compound developed treat prevent viral influenza humans gilead codeveloped tamiflu f hoffmannla roche ltd hoffmannla roche inc collectively roche roche owns worldwide commercial rights tamiflu required pay gilead royalty net sales product october fda approved tamiflu treatment influenza adults roche began selling product commercially record royalty revenue roche quarter following quarter related tamiflu sales occur accordingly gilead began recognizing royalties tamiflu first quarter expect tamiflu royalties increase result broader market penetration additional regulatory approvals received second half time period tamiflu approved us prophylaxis preventive adults treatment influenza children approved japan treatment influenza adults substantially remaining net royalty revenue recognized represents royalties sales vistide pharmacia sa pharmacia outside united states future periods royalties sales vistide expected relatively flat decline slightly december securities exchange commission issued staff accounting bulletin sab revenue recognition financial statements among things sab describes sec staff 's position recognition certain nonrefundable upfront fees received connection collaboration agreements previously recognized nonrefundable technology access fees received connection collaboration agreements revenue received collectibility probable technology transferred effective january changed method accounting fees recognize related manufacturing obligation fulfilled straightline basis term related research development collaboration manufacturing supply arrangement appropriate method best matches effort provided believe change accounting principle preferable based guidance provided sab cumulative effect change accounting principle recorded fourth quarter retroactively effective january deferred revenue recognized contract revenue remaining term research development manufacturing supply arrangements appropriate year ended december impact cumulative change accounting principle increase net loss million recognized additional contract revenue million accordance sab related front fees received prior years million related three collaborative arrangements million related initial licensing fee sumitomo million related initial licensing fee roche million related initial license fee pharmacia remaining million related deferred revenue december results sumitomo pharmacia collaborations expected recognized contract revenue next twelve years remaining deferred revenue related roche initial license fee december pro forma results included consolidated statements operations part iv reflect amounts would reported change accounting principle applied retroactively total contract revenue million compared million million single significant source contract revenue three years payments roche relating development tamiflu rd collaboration agreement gilead roche recorded contract revenue roche million million million million contract revenue roche included million milestone payments related roche completing regulatory filings approvals tamiflu us japan million rd expense reimbursements million resulting adoption sab discussed amount included million milestone payments million rd reimbursements million recorded represented reimbursements rd expenses included million attributable rd expenses incurred fourth quarter subject roche 's approval december expenses approved reimbursement recognized revenue rd reimbursements roche decreased compared reimbursements similarly decreased relative tamiflu development efforts ramp roche 's commercialization activities increased december gilead entitled additional milestone payments million upon roche achieving certain developmental regulatory milestones may earn milestones payments roche agreement expect expense reimbursements roche agreement continue decline reimbursements approximate actual related costs incurred march entered agreement eyetech pharmaceuticals inc relating gilead 's proprietary aptamer nx currently early clinical trials nx inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses nx product successfully commercialized eyetech pay us royalties worldwide sales product eyetech also responsible research development costs provide clinical supplies product eyetech march received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue agreement remainder license fee recognized revenue first quarter also entitled additional cash payments eyetech million eyetech reaches certain nx development milestones additionally gilead received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors obligated transfer total shares subject warrant university colorado boulder collaborative agreement university expect retain remaining shares recognize revenue related warrant readily determinable fair value time transaction november gilead somalogic inc entered agreement gilead assigned somalogic sole exclusive license certain intellectual property including patents patent applications terms agreement somalogic required pay gilead total million two nonrefundable installments second installment totaled million received november recorded contract revenue upon receipt first installment million received recognized contract revenue november contract revenue recognized also included million performancebased milestone payment received skw americas inc skw skw owner proligo llc proligo entity hold remaining ownership interest recorded contract revenue million milestone payment sumitomo pharmaceuticals co ltd related license ambisome rights japan also entered agreement isis pharmaceuticals inc isis sold isis holdings antisense patent estate including patents patent applications terms agreement isis required pay gilead total million four installments total sale price million included contract revenue contract revenue also includes reimbursement research expenses collaborative agreements glaxosmithkline formerly glaxo wellcome inc glaxo schering ag schering agreement schering related discovery development aptamers vivo diagnostic agents schering research agreement recognized million contract revenue schering research agreement expired related license agreement remains effect collaborative agreement glaxo related code blocker program contract revenue recognized connection glaxo agreement million cost goods sold cost goods sold million compared million million percentage product sales revenue cost goods sold connection european product sales price products currency country products sold payment currencies significant majority manufacturing cost us dollars decline value payment currencies relative us dollar negatively impact gross margins since manufacturing costs remain approximately revenues reported us dollars decline gross margin negatively impacted factors discussed product sales section caption revenues excluding impact foreign exchange rates reported sales revenue cost sales percentage sales would approximately slightly primarily due larger production quantities absorbing fixed costs cost sales percentage annual basis range recent years except potential impact unpredictable uncontrollable changes payment currencies relative us dollar expect cost sales percentage sales revenue remain materially consistent rate future years changes nature mix product sales could impact relationship operating expenses research development rd expenses million compared million million major development projects include tenofovir df hiv adefovir dipivoxil hepatitis b virus hbv incurred increased costs programs phase iii clinical trials additionally made upfront payments fourth quarter inlicense two oncology products glaxo southern research institute increases offset significantly lower expenses development adefovir dipivoxil hiv program discontinued fourth quarter expect rd expenses approximately higher due increased spending continued latestage development tenofovir df hiv adefovir dipivoxil hbv decrease rd expenses compared primarily attributable reduced research activities boulder colorado facility august transferred boulderbased nexstar technology products division proligo equity investee addition october reduced rd workforce boulder employees recorded expense million related severance packages discharged employees reduced rd workforce boulder employees upon completing merger nexstar finally gilead reduced level involvement development tamiflu compared decreases offset part greater levels expense development programs adefovir dipivoxil hbv tenofovir df hiv well adjustment million fully reserve supply adefovir dipivoxil hiv adjustment made result decision discontinue development product candidate united states negative recommendation fda advisory panel selling general administrative sga expenses million compared million million major factor contributing decrease levels inclusion sga million mergerrelated expenses excluding merger expenses sga expenses essentially flat compared higher general administrative ga expenses offset savings sales marketing expenses increased ga spending included costs implement new upgraded information technology systems legal costs incurred connection new collaboration agreements various corporate projects expenses meet general corporate reporting requirements sales marketing expenses included costs expand sales marketing capacity anticipation thenplanned commercial launch adefovir dipivoxil hiv discontinued fourth quarter additionally sales marketing expenses reflect cost savings us elimination second half duplicate positions functions within combined gilead nexstar organization expect sga expenses higher levels primarily due activities necessary prepare anticipated us european commercial launch tenofovir df increase sga expenses compared due merger expenses million excluding merger expenses sga spending flat recorded million compensation expense related nexstar stock option plan requires use variable plan accounting charge substantially offset cost savings related elimination duplicate selling general administrative positions functions within combined gilead nexstar organization second half merger expenses million included total sga expenses expenses primarily consisted transaction costs including professional fees filing fees printing costs employee severance costs writedown certain nexstar property equipment expected used future operations total employee severance costs million relate termination employees majority boulder colorado facility december employees severance costs accrued terminated balance accrued liability million december substantially remaining accrued severance costs paid former employees december expect realize cost savings resulting staff reductions occurred merger litigation settlement related expenses incurred litigation settlement related expenses million million million reached settlement elan corporation plc elan successor company liposome company companies agreed dismiss legal proceedings involving ambisome gilead 's liposomal formulation amphotericin b terms settlement agreement made initial payment elan million required make additional payments based ambisome sales payments subject certain minimum maximum amounts million accounting charge recorded representing net present value future minimum payments required make record expense quarter based difference future minimum payments amount previously accrued amounts significant expect difference future minimum maximum payments elan material gain sale subsidiary recognized million gain sale interest newly established subsidiary proligo delaware limited liability company skw proligo formed july initially consisted assets nexstar technology products division manufacturer oligonucleotides specialty chemicals pharmaceuticals industry payment sale interest proligo received million interest perseptive biosystems gmbh company hamburg germany specializes manufacture nucleoside phosphoramidite monomers addition skw agreed pay us million guaranteed payments million performancebased milestones part transaction contributed million interest perseptive biosystems gmbh proligo interest perseptive biosystems gmbh fair value approximately million skw contributed million remaining perseptive biosystems proligo interest income interest expense reported interest income million compared million million increase due higher interest rates investment portfolio well slightly higher average balances invested funds decrease interest income compared due declining balance invested cash well slightly lower investment returns expect interest income increase levels due higher cash balances result million convertible subordinated notes financing completed december incurred interest expense million compared million million decrease occurred primarily incurred interest expense convertible debentures august converted common stock interest expense debt including capital leases decreased also due continually declining outstanding balances repay debt decrease however offset interest new million convertible subordinated notes issued december interest expense decreased compared primarily due repayment debt obligations including capital leases expect interest expense increase approximately three times expense level incur full year expense million convertible subordinated notes equity loss unconsolidated affiliate gilead recorded million equity loss unconsolidated affiliate proligo represented share proligo 's loss thirteenmonth period ended december fourth quarter proligo changed fiscal yearend december november recorded million equity loss proligo proligo 's fiscal year ended november recorded million equity loss proligo period august proligo 's inception date november expect continue recognize losses equity investment proligo investment proligo reported noncurrent assets consolidated balance sheet carrying amount investment million december million december threeyear period ended december funded proligo total million maintain percentage ownership interest proligo commitments provide additional funding proligo expect provide liquidity capital resources cash cash equivalents marketable securities totaled million december million december increase million due net proceeds million million convertible subordinated notes financing december major sources uses cash included proceeds issuances stock employee stock plans offset cash used fund operating activities capital expenditures significant changes working capital included increase accrued clinical preclinical expenses million primarily due advanced accelerated phase iii clinical trials tenofovir df hiv adefovir dipivoxil hbv accrued liabilities increased million largest component unrealized loss foreign exchange contracts million december unrealized loss partially offset unrealized foreign exchange gains accounts receivable balances date however gain receivables included accounts receivable balance balance sheet components increase accrued liabilities included higher marketing accruals various accruals due timing invoice receipts higher foreign tax liabilities primarily italy another significant change working capital increase accounts payable approximately million primarily due timing payments vendors accounts receivable balance december million compared million december growth primarily due increased receivable balances countries payments tend relatively slow certain cases slow payment practices reflect pace governmental entities reimburse customers sales customers countries tend relatively slow paying past increased future may increase average length time accounts receivable outstanding turn may increase financial risk related certain customers certain countries payments slow particularly greece spain italy accounts receivable significant december past due accounts receivable greece spain italy totaled approximately million approximately million days past due december past due receivables countries million approximately million days past due date experienced modest losses respect collection accounts receivable believe past due accounts receivable greece spain italy collectible continually seek improve collection process ensure fully collect amounts due us based product sales collections timely noncurrent assets increased million december million december increase primarily due million longterm prepaid royalties recorded fourth quarter related payments made iocbrega prepayments amortized royalty expense expected commercial life tenofovir df adefovir dipivoxil fda approval obtained sales products commence also included noncurrent assets december million deferred debt issuance costs related million convertible subordinated notes financing completed december costs amortized interest expense contractual term notes increases noncurrent assets offset million decrease due receivable isis related payment due us december balance reclassified current assets december additionally noncurrent assets december included deferred debt issuance costs million related subordinated debentures converted common stock august costs reclassified additional paidin capital upon conversion longterm deferred revenue december million balance represents upfront payments received two collaboration agreements recognized contract revenue life related research development collaboration manufacturing supply arrangement upon adoption sab effective january total million previously recognized contract revenue recorded deferred revenue million recognized contract revenue made capital expenditures million million million expenditures primarily facilities improvements accommodate growth well laboratory manufacturing equipment expect capital spending continue level higher future particularly accommodate expanded research development activities august redeemed convertible subordinated debentures cash price per principal amount debentures outstanding plus accrued interest redemption price provided original debentures indenture upon redemption entire million principal amount debentures outstanding time converted newly issued shares gilead common stock august deferred debt issuance costs million related debentures charged additional paid capital connection conversion debentures common stock december issued million convertible subordinated notes due december private offering notes currently convertible total shares gilead common stock per share conversion price higher common stock price notes ' issuance date notes redeemable whole part option time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes maintain million unsecured line credit bears interest floating rate major financial institution terms line credit required maintain certain financial ratios limitations ability incur additional debt engage certain significant transactions line credit includes foreign exchange facility expires april currently intend renew line expires maintain foreign exchange facility december outstanding borrowings line believe existing capital resources supplemented net product revenues contract royalty revenues adequate satisfy capital needs foreseeable future december entitled additional cash payments million roche roche achieves specific additional tamiflu developmental regulatory milestones also entitled additional cash payments eyetech million eyetech reaches certain nx development milestones assure milestones met future capital requirements depend many factors including progress research development efforts scope results preclinical studies clinical trials cost timing outcome regulatory reviews rate technological advances determinations commercial potential products development commercial performance ambisome products development receive marketing approval administrative expenses status competitive products establishment manufacturing capacity thirdparty manufacturing arrangements expansion sales marketing capabilities possible geographic expansion establishment additional collaborative relationships companies may future require additional funding could form proceeds equity debt financings additional collaborative agreements corporate partners funding required assure available favorable terms prospective accounting pronouncement statement financial accounting standards sfas accounting derivative instruments hedging activities amended sfas accounting derivative instruments hedging activitiesdeferral effective date fasb statement sfas accounting certain derivative instruments certain hedging activities effective gilead january standards require recognize derivatives either assets liabilities measured fair value derivative designated meets definition fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings derivative designated meets definition cash flow hedge effective portions changes fair value derivative recorded comprehensive income recognized income statement hedged item affects earnings ineffective portions changes fair value cash flow hedges recognized earnings immediately sfas also requires warrants purchase capital stock nonpublic company include net settlement feature recorded balance sheet fair value offsetting amount recorded results operations fair value warrants required remeasured balance sheet date changes fair value warrants recorded results operations cash flow hedges warrants private companies net settlement feature covered sfas upon adoption sfas january recognize aggregate credit results operations recorded cumulative change accounting principle approximately million increase net assets approximately million increase comprehensive income approximately million market risk disclosures foreign currency exchange risk operations include manufacturing sales activities united states well sales activities europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes exchange rates us dollar various foreign currencies significant euro british pound australian dollar us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business mitigate impact changes currency exchange rates cash flows foreign currency sales transactions enter foreign exchange forward contracts hedge foreign currencydenominated accounts receivable additionally mitigate impact currency rate fluctuations cash outflows certain foreign currencydenominated raw materials purchases enter foreign exchange forward contracts hedge foreign currencydenominated accounts payable following table summarizes notional amounts average currency exchange rates fair values open foreign exchange forward contracts december contracts maturities one year less one exception one hedge contract intended hedge raw materials purchases first quarter notional amount million fair value million maturity months average rates stated terms amount foreign currency per us dollar fair values represent estimated settlement amounts december notional amounts fair values us thousands fair value currency notional amount average rate december australian dollar british pound danish krone euro norwegian krone swedish krona swiss franc french franc interest rate risk portfolio availableforsale investment securities fixedrate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestbearing assets fixedrate liabilities december dollars thousands years ending december fair value december thereafter total assets availableforsale securities average interest rate liabilities minimum litigation settlement including current portion discount rate longterm obligations including current portion average interest rate convertible subordinated debentures interest rate longterm obligations consist capital leases debt secured property plant equipment interest portion payments due included item quantitative qualitative disclosures market risk quantitative qualitative disclosure market risk included caption market risk disclosures item item financial statements supplementary data financial statements required item set forth beginning report item changes disagreements accountants accounting financial disclosure applicable part iii item directors executive officers registrant information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed sec pursuant regulation connection annual meeting proxy statement headings nominees executive officers compliance section securities exchange act item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee report item security ownership certain beneficial owners management information required item incorporated reference section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions information required item incorporated reference sections proxy statement headings compensation committee interlocks insider participation certain transactions executive compensation part iv item exhibits financial statement schedules reports form k following documents filed part schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document amended restated certificate incorporation registrant amended bylaws registrant amended restated march reference made exhibit exhibit amended restated rights agreement dated october registrant chasemellon shareholder services llc agreement plan merger dated february among registrant gazelle acquisition sub inc nexstar pharmaceuticals inc indenture dated december registrant chase manhattan bank trust company national association including therein forms notes registration rights agreement dated december registrant jp morgan securities inc chase securities inc lehman brothers inc morgan stanley co incorporated form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees registrant 's incentive stock option plan related agreements registrant 's supplemental stock option plan related agreements registrant 's employee stock purchase plan amended march registrant 's stock option plan amended restated april form nonqualified stock option issued certain executive officers directors relocation loan agreement dated november among registrant john c martin rosemary martin vintage park research development net lease registrant vintage park associates dated march premises located b lakeside drive foster city california related addendum exhibits amendments exhibit exhibit footnote number description document letter agreement dated september registrant iocb rega exhibits certain confidential information omitted vintage park research development net lease registrant vintage park associates dated september premises located lakeside drive foster city california related exhibits amendment agreement dated october registrant iocb rega related license agreements exhibits certain confidential information omitted amendment agreement dated december registrant iocb rega patent rights purchase agreement registrant isis pharmaceuticals inc dated december certain confidential information omitted loan agreement dated october among registrant mark l perry melanie p pena registrant 's nonemployee directors ' stock option plan amended january related form stock option grant vintage park research development lease registrant wcb sixteen limited partnership dated june premises located lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limited partnership dated june premises located lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limited partnership dated june premises located b lakeside drive foster city california license supply agreement registrant pharmacia upjohn sa dated august certain confidential information omitted development license agreement registrant f hoffmannla roche ltd hoffmannla roche inc dated september certain confidential information omitted amendment vintage park research development lease registrant spieker properties lp dated august premises located lakeside drive foster city california nexstar pharmaceuticals inc 's incentive stock plan adopted february amended nexstar pharmaceuticals inc 's director option plan adopted july vestar inc stock option plan lease dated march vestar inc majestic realty co patrician associates inc amendment thereto amendment thereto dated june exhibit exhibit footnote number description document third amendment dated january majestic realty co patrician associates inc registrant lease dated march vestar inc majestic realty co patrician associates inc assignment royalty agreement dated december effective june vestar inc city hope national medical center license agreement effective august vestar inc regents university california agreement fujisawa usa inc vestar inc dated august amendment thereto dated may amendment agreement fujisawa usa inc vestar inc dated april fujisawa usa inc vestar inc certain confidential information omitted amendment agreement fujisawa usa inc registrant dated march agreement fujisawa usa inc vestar inc dated august lease dated april vestar inc majestic realty co patrician associates inc first amendment lease dated april majestic realty co patrician associates inc vestar inc amending lease dated april majestic realty co patrician associates inc vestar inc industrial real estate lease dated july wilderness place ltd nexstar pharmaceuticals inc sublease agreement dated july sybase inc nexstar pharmaceuticals inc license distribution agreement dated september sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc certain confidential information omitted settlement agreement dated august among nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omitted amended restated limited liability company agreement proligo llc dated august among nexstar pharmaceuticals international inc skw americas inc nexstar pharmaceuticals inc amendment dated april sumitomo pharmaceuticals co ltd nexstar pharmaceuticals inc license distribution agreement dated september sumitomo nexstar pharmaceuticals inc officelight manufacturing lease thw partners limited partnership registrant dated january subsidiaries registrant consent ernst young llp independent auditors consent pricewaterhousecoopers llp independent auditors exhibit exhibit footnote number description document power attorney reference made signature filed exhibit registrant 's annual report fiscal year ended december incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's current report form k filed october incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's annual report fiscal year ended march incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended june incorporated herein reference filed exhibit registrant 's quarterly report form q quarter ended september incorporated herein reference filed exhibit registrant 's current report form k filed march incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's fiscal year ended december incorporated herein reference filed march exhibit nexstar pharmaceuticals inc 's registration statement form file incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended june incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarterly period ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarter ended september incorporated herein reference filed exhibit nexstar pharmaceuticals inc 's form q quarter ended june incorporated herein reference filed exhibit registrant 's year ended december incorporated herein reference filed exhibit registrant 's year ended december incorporated herein reference filed exhibit registrant 's year ended december incorporated herein reference filed exhibit registrant 's registration statement form amended incorporated herein reference b reports form k december registrant filed current report form k relating intention sell convertible subordinated notes december registrant filed current report form k relating entering agreement sell convertible subordinated notes january registrant filed current report form k relating entering agreement cubist pharmaceuticals inc gilead sciences inc consolidated financial statements years ended december contents report independent auditors audited consolidated financial statements consolidated balance sheets consolidated statements operations consolidated statement stockholders ' equity consolidated statements cash flows notes consolidated financial statements report ernst young llp independent auditors board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc subsidiaries december related consolidated statements operations stockholders ' equity cash flows three years period ended december audits also included financial statement schedule listed item annual report financial statements schedule responsibility management gilead sciences inc responsibility express opinion financial statements schedule based audits audit financial statements proligo llc limited liability company investment reflected accompanying consolidated financial statements using equity method accounting investment proligo llc represents consolidated total assets december respectively company 's equity net loss proligo llc respectively financial statements proligo llc audited auditors whose report furnished us insofar opinion consolidated financial statements relates data included proligo llc based solely report conducted audits accordance auditing standards generally accepted united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits report auditors provide reasonable basis opinion opinion based audits report auditors consolidated financial statements referred present fairly material respects consolidated financial position gilead sciences inc subsidiaries december consolidated results operations cash flows three years period ended december conformity accounting principles generally accepted united states also opinion financial statement schedule referred considered relation basic financial statements taken whole presents fairly material respects information set forth therein discussed note consolidated financial statements effective january company changed method accounting nonrefundable upfront fees received connection collaboration agreements ernst young llp palo alto california january report independent accountants board directors members proligo llc opinion accompanying consolidated balance sheets related consolidated statements operations members ' equity cash flows present fairly material respects financial position proligo llc subsidiaries december november results operations cash flows thirteenmonths ended december year ended november period august november respectively conformity accounting principles generally accepted united states america financial statements responsibility company 's management responsibility express opinion financial statements based audits conducted audits statements accordance auditing standards generally accepted united states america require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecoopers llp broomfield colorado january gilead sciences inc consolidated balance sheets thousands except share per share amounts december assets current assets cash cash equivalents marketable securities accounts receivable net allowance doubtful accounts inventories prepaid expenses total current assets property plant equipment net noncurrent assets liabilities stockholders ' equity current liabilities accounts payable accrued clinical preclinical expenses accrued compensation employee benefits accrued liabilities deferred revenue longterm obligations due within one year total current liabilities longterm deferred revenue accrued litigation settlement expenses due one year longterm obligations due one year convertible subordinated debt commitments contingencies see accompanying notes stockholders ' equity preferred stock par value per share issuable series shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december shares issued outstanding december additional paidin capital accumulated comprehensive loss deferred compensation accumulated deficit total stockholders ' equity see accompanying notes gilead sciences inc consolidated statements operations thousands except per share amounts year ended december revenues product sales net royalty revenue net contract revenue contract revenuesab total revenues expenses cost goods sold research development selling general administrative total costs expenses loss operations gain sale majority interest subsidiary interest income interest expense loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle provision income taxes equity loss unconsolidated affiliate loss cumulative effect change accounting principle cumulative effect change accounting principle net loss basic diluted net loss per common share loss cumulative effect change accounting principle cumulative effect change accounting principle net loss pro forma amounts assuming change accounting principle applied retroactively net loss basic diluted net loss per common share common shares used calculate basic diluted net loss per common share see accompanying notes gilead sciences inc consolidated statement stockholders ' equity thousands except share amounts accumulated common stock additional comprehensive preferred paidin income deferred accumulated stock shares amount capital loss compensation deficit balance december net loss unrealized loss availableforsale investments net foreign currency translation adjustment comprehensive loss private issuance common stock employee stock purchase plan option exercises amortization deferred compensation compensatory stock transactions balance december net loss unrealized loss availableforsale investments net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercises net warrant exercises net conversion shares preferred stock conversion convertible subordinated debentures amortization deferred compensation compensatory stock transactions balance december net loss unrealized gain availableforsale investments net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercises net warrant exercises net conversion convertible subordinated debentures amortization deferred compensation compensatory stock transactions balance december total stockholders ' equity balance december net loss unrealized loss availableforsale investments net foreign currency translation adjustment comprehensive loss private issuance common stock employee stock purchase plan option exercises amortization deferred compensation compensatory stock transactions balance december net loss unrealized loss availableforsale investmentsnet foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercises net warrant exercises net conversion shares preferred stock conversion convertible subordinated debentures amortization deferred compensation compensatory stock transactions balance december net loss unrealized gain availableforsale investments net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercises net warrant exercises net conversion convertible subordinated debentures amortization deferred compensation compensatory stock transactions balance december see accompanying notes gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net loss adjustments reconcile net loss net cash used operating activities depreciation amortization net effect change accounting principle compensation expense stock option transactions gain sale majority interest subsidiary equity loss unconsolidated affiliate litigation settlement charges net provision doubtful accounts reduction allowance note receivable net unrealized gain loss foreign currency transactions changes operating assets liabilities accounts receivable inventories prepaid expenses assets longterm prepaid royalties accounts payable accrued liabilities deferred revenue excluding net effect change accounting principle net cash used operating activities investing activities purchases marketable securities sales marketable securities maturities marketable securities capital expenditures proceeds sale majority interest subsidiary net closing costs investment unconsolidated affiliate payments received note receivable net cash provided used investing activities financing activities proceeds issuances common stock payments shortterm borrowings net proceeds issuance longterm debt repayments longterm debt proceeds issuance convertible subordinated notes net issuance costs net cash provided financing activities effect exchange rate changes cash net increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year see accompanying notes gilead sciences inc consolidated statements cash flows continued thousands year ended december supplemental disclosure cash flow information interest paid income taxes paid disclosures gain sale majority interest subsidiary cash receipts net closing costs receipt interest manufacturing facility net present value guaranteed payments net book value interest sold noncash investing financing activities purchase equipment leasehold improvements accounts payable common stock issued upon conversion debentures reclassification deferred debt issuance costs additional paidin capital upon conversion subordinated debentures see accompanying notes gilead sciences inc notes consolidated financial statements december organization summary significant accounting policies overview gilead sciences inc company gilead incorporated delaware june independent biopharmaceutical company seeks provide accelerated solutions patients people care company discovers develops manufactures commercializes proprietary therapeutics challenging infectious diseases viral fungal bacterial infections cancer gilead also expertise liposomal drug delivery technology currently company markets ambisomeregistered trademark amphotericin b liposome injection antifungal agent daunoxomeregistered trademark daunorubicin citrate liposome injection drug approved treatment kaposi 's sarcoma vistideregistered trademark cidofovir injection treatment cytomegalovirus cmv retinitis hoffmannla roche inc markets tamiflutm oseltamivir phosphate treatment influenza collaborative agreement gilead addition gilead developing products treat diseases caused human immunodeficiency virus hiv hepatitis b virus hbv bacterial infections cancer fully described note july gilead entered business combination merger nexstar pharmaceuticals inc nexstar business combination accounted pooling interests historical consolidated financial statements gilead years prior business combination restated include financial position results operations cash flows nexstar material adjustments necessary conform accounting policies two companies costs merger charged operations accompanying consolidated financial statements include accounts company wholly majorityowned subsidiaries significant intercompany transactions eliminated certain prior period amounts reclassified consistent current presentation stock split february gilead completed twoforone stock split effected form stock dividend stockholders record february accordingly share per share amounts periods presented restated retroactively reflect split cumulative effect change accounting principle year ended december gilead adopted securities exchange commission 's staff accounting bulletin sab revenue recognition financial statements resulting cumulative effect change accounting principle see note use estimates preparation financial statements conformity generally accepted accounting principles requires management make estimates assumptions affect amounts reported consolidated financial statements accompanying notes actual results could differ estimates gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued revenue recognition product sales revenue recognized upon passage legal title inventory satisfaction company 's performance obligations company provide customers general right product return however company accept returns product expired deemed damaged defective provisions made doubtful accounts estimated product returns cash discounts government discounts rebates connection european product sales company prices products currency country sold payment currencies significant majority company 's manufacturing costs us dollars therefore decline value payment currencies relative us dollar likely negatively impact gross margins since company 's manufacturing costs would remain approximately revenue terms us dollars would decline periodically company 's gross margin adversely affected currency fluctuations contract revenue research development recorded earned based performance requirements contract nonrefundable contract fees performance obligations exist continuing involvement gilead recognized earlier payments received collection assured revenue nonrefundable upfront license fees continue involvement development collaboration obligation supply product recognized manufacturing obligation fulfilled ratably development period period manufacturing obligation appropriate based substantive risk assessment revenue associated substantive performance milestones recognized based upon achievement milestones defined respective agreements revenue research development cost reimbursement contracts recognized related costs incurred advance payments received excess amounts earned classified deferred revenue royalty revenue sales ambisome recognized month following corresponding sales occur royalty revenue sales vistide tamiflu recognized received quarter following quarter corresponding sales occur research development costs rd costs including funded third parties charged expense incurred stockbased compensation accordance provisions statement financial accounting standards sfas accounting stockbased compensation company elected follow accounting principles board opinion apb accounting stock issued employees related interpretations accounting employee stock option plans apb exercise price company 's employee director stock options equals exceeds fair value gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued underlying stock date grant compensation expense recognized see note pro forma disclosures stockbased compensation pursuant sfas march financial accounting standards board fasb issued interpretation fin accounting certain transactions involving stock compensationan interpretation apb opinion fin clarifies application apb respect stockrelated compensation gilead 's adoption fin july material effect financial position results operations gilead basic diluted loss per common share periods presented basic diluted loss per common share computed based weighted average number common shares outstanding period convertible notes stock options warrants could potentially dilute basic earnings per share future instruments well convertible debentures previously outstanding excluded computation diluted loss per share effect antidilutive periods presented share per share amounts periods presented restated retroactively reflect twoforone stock split february cash cash equivalents company considers highly liquid investments insignificant interest rate risk remaining maturity three months less purchase date cash equivalents gilead may enter overnight repurchase agreements purchases securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents company 's investment policy may enter repurchase agreements repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold gilead marketable securities management determines appropriate classification gilead 's marketable debt securities time purchase reevaluates designation balance sheet date company 's marketable debt securities classified availableforsale carried estimated fair values reported either cash equivalents marketable securities december cash cash equivalents include million securities designated availableforsale million december unrealized gains losses available forsale securities excluded earnings reported separate component stockholders ' equity interest income includes interest dividends amortization purchase premiums discounts realized gains losses sales securities cost securities sold based specific identification method concentrations credit risk gilead subject credit risk portfolio cash equivalents marketable securities policy company limits amounts invested securities maturity industry group investment gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued type issuer except securities issued us government gilead exposed significant concentrations credit risk financial instruments goals company 's investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return gilead also subject credit risk accounts receivable related product sales majority company 's trade accounts receivable arises sales ambisome primarily sales company 's european subsidiaries export sales distributors europe company performs credit evaluations customers ' financial condition generally required collateral date company experienced modest credit losses respect accounts receivable inventories inventories recorded lower cost market cost determined firstin firstout basis management periodically reviews composition inventory order identify obsolete slowmoving otherwise unsaleable items items observed alternate uses inventory company record writedown net realizable value period units identified impaired historically inventory writedowns insignificant consistent management 's expectations property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method estimated useful lives follows description estimated useful life years buildings laboratory manufacturing equipment office computer equipment office computer equipment includes capitalized computer software company 's capitalized software purchased company internally developed computer software leasehold improvements capitalized leased equipment amortized shorter lease term item 's useful life noncurrent assets noncurrent assets december includes million including withholding taxes approximately million prepaid royalties paid institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega discussed iocbrega caption note also included noncurrent assets december deferred debt issuance costs million related million subordinated convertible notes gilead issued december noncurrent assets gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued december included million deferred debt issuance costs related subordinated convertible debentures gilead called debentures redemption august time converted gilead common stock upon conversion remaining balance deferred debt issuance costs debentures charged additional paid capital longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment us food drug adminstration another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated incomeproducing asset indication impairment company confirm comparing estimated future cash flows expected result use asset eventual disposition carrying amount asset estimating future cash flows assets grouped lowest level identifiable cash flows largely independent cash flows generated asset groups sum expected future cash flows undiscounted without interest changes less carrying amount asset impairment loss measured excess carrying value asset fair value recognized cash flow estimates used calculations based management 's best estimates using appropriate customary assumptions projections time current accrued liabilities december december accrued liabilities included million accrued litigation settlement costs see legal proceedings discussion note foreign currency translation transactions contracts adjustments resulting translating financial statements company 's foreign subsidiaries us dollars excluded determination net income accumulated separate component stockholders ' equity net foreign exchange transaction losses reported gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued selling general administrative expense consolidated statements operations losses million million million company hedges certain foreign currency exposures related outstanding trade accounts receivable firmly committed purchase transactions foreign exchange forward contracts general contracts expose company market risk gains losses contracts offset gains losses transactions hedged company 's exposure credit risk contracts function changes interest currency exchange rates therefore varies time gilead limits risk counterparties contracts may unable perform transacting major us banks company also limits risk loss entering contracts provide net settlement maturity therefore company 's overall risk loss event counterparty default limited amount unrecognized unrealized gains outstanding contracts ie contracts positive fair value date default company enter speculative foreign currency transactions write options accounting hedges accounts receivable company 's aggregate net foreign currency transaction gain loss reported selling general administrative expense company recognizes net unrealized gain loss outstanding forward contracts based difference contract exchange rate market exchange rate balance sheet date respect hedges firmly committed purchase transactions unrealized gains losses underlying forward contracts deferred reported component related transaction period occurs december company net unrealized losses open foreign exchange forward contracts million company forward exchange contracts outstanding million december million december contracts maturities one year less one exception one hedge contract intended hedge raw materials purchases first quarter notional amount million fair value million maturity thirteen months company presently hedge net investment foreign subsidiaries forecasted foreign currency denominated sales fair value financial instruments company 's financial instruments consist principally cash cash equivalents marketable securities accounts receivable certain noncurrent assets forward foreign exchange contracts accounts payable longterm obligations convertible subordinated notes cash cash equivalents marketable securities forward foreign exchange contracts hedge accounts receivable reported respective fair values balance sheet forward foreign exchange contracts hedge firmly committed purchases recorded fair value net related deferred gain loss resulting reported net balance zero management believes remaining financial instruments exception convertible subordinated notes reported balance sheet amounts approximate current fair values fair value convertible subordinated notes december million carrying value million fair value notes gilead sciences inc notes consolidated financial statements continued december organization summary significant accounting policies continued determined multiplying number shares notes converted per share market price gilead 's common stock december plus accrued interest fair value gilead 's prior convertible subordinated debentures redeemed converted gilead common stock third quarter million december carrying value million date fair value debentures december determined obtaining quote market maker debentures prospective accounting pronouncement statement financial accounting standards sfas accounting derivative instruments hedging activities amended sfas accounting derivative instruments hedging activitiesdeferral effective date fasb statement sfas accounting certain derivative instruments certain hedging activities effective company january standards require company recognize derivatives either assets liabilities measured fair value derivative designated meets definition fair value hedge changes fair value derivative hedged item attributable hedged risk recognized earnings derivative designated meets definition cash flow hedge effective portions changes fair value derivative recorded comprehensive income recognized income statement hedged item affects earnings ineffective portions changes fair value cash flow hedges recognized earnings immediately sfas also require warrants purchase capital stock nonpublic company include net settlement feature recorded balance sheet fair value offsetting amount recorded results operations fair value warrants required remeasured balance sheet date changes fair value warrants recorded results operations gilead cash flow hedges warrants private companies net settlement feature covered sfas upon adoption sfas january gilead recognize aggregate credit results operations recorded cumulative change accounting principle approximately million increase net assets approximately million increase comprehensive income approximately million cumulative change accounting principle december securities exchange commission issued staff accounting bulletin sab revenue recognition financial statements among things sab describes sec staff 's position recognition certain nonrefundable upfront fees received connection collaboration agreements company previously recognized nonrefundable technology access fees received connection collaboration agreements revenue received collectibility probable technology transferred effective january gilead changed method accounting fees recognize related manufacturing obligation fulfilled straightline basis term related research development collaboration manufacturing supply arrangement appropriate method best matches effort provided management believes change accounting principle preferable based guidance provided sab gilead sciences inc notes consolidated financial statements continued december cumulative change accounting principle continued cumulative effect change accounting principle recorded fourth quarter retroactively effective january deferred revenue recognized contract revenue remaining term research development manufacturing supply arrangements appropriate year ended december net impact change accounting principle increase net loss million per share loss consists million cumulative effect change january net million related deferred revenue recognized contract revenue year remainder million related deferred revenue balance december expected recognized revenue fiscal years pro forma results included consolidated statements operations reflect amounts would reported change accounting principle applied retroactively acquisition nexstar july company acquired outstanding common stock nexstar delaware corporation agreement dated february result nexstar became wholly owned subsidiary gilead connection merger gilead issued total million shares gilead common stock share gilead common stock share nexstar common stock nexstar 's stockholders consideration shares common stock nexstar addition holders options warrants outstanding time merger purchase aggregate approximately million shares nexstar common stock would receive upon exercise options warrants fraction share gilead common stock holders million principal amount convertible subordinated debentures nexstar received right convert debentures approximately million shares gilead common stock merger qualified taxfree reorganization accounted pooling interests table presents separate results operations gilead nexstar periods prior merger combined results merger thousands mergerrelated gilead nexstar adjustments total year ended december revenues net income loss year ended december revenues net income loss b mergerrelated costs b adjustment required conform accounting policy nexstar 's policy capitalize certain patent trademark costs gilead 's policy charge items selling general administrative expense period incurred accompanying financial statements restated periods patent trademark costs expensed incurred gilead sciences inc notes consolidated financial statements continued december acquisition nexstar continued result merger nexstar company incurred mergerrelated costs consisting transaction costs primarily professional fees filing fees printing costs related charges employee severance costs writedown certain nexstar assets would used continuing operations following table shows details merger related costs accruals december thousands charged expense december december utilized accrual balance merger transaction costs employee severance writedown nexstar assets na na total employees severance costs accrued terminated december substantially remaining accrued severance costs paid former employees december merger transaction costs utilized december availableforsale securities following summary availableforsale securities estimated fair values availableforsale securities based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december us treasury securities obligations us government agencies certificates deposit corporate debt securities assetbacked securities debt securities total december us treasury securities obligations us government agencies certificates deposit corporate debt securities assetbacked securities debt securities total gilead sciences inc notes consolidated financial statements continued december availableforsale securities continued debt securities consist primarily money market funds following table presents certain information related sales availableforsales securities thousands year ended december proceeds sales gross realized gains sales gross realized losses sales december million company 's portfolio marketable securities excluding million assetbacked securities contractual maturity less one year million portfolio contractual maturity greater one year less three years none estimated maturities company 's assetbacked securities exceed three years collaborative arrangements contracts eyetech march gilead entered agreement eyetech pharmaceuticals inc relating gilead 's proprietary aptamer nx currently early clinical trials nx inhibitor vascular endothelial growth factor vegf known play role development certain ophthalmic diseases terms agreement eyetech received worldwide rights therapeutic uses nx product successfully commercialized eyetech pay gilead royalties worldwide sales product eyetech also responsible research development costs gilead provide clinical supplies product eyetech march gilead received million upfront licensing fee eyetech april recognized revenue ratably oneyear supply agreement period accordingly million license fee recorded contract revenue agreement remainder license fee recognized revenue first quarter gilead also entitled additional cash payments eyetech million eyetech reaches certain nx development milestones additionally gilead received warrant purchase shares eyetech series b convertible preferred stock exercisable price per share price stock issued investors gilead obligated transfer shares subject warrant university colorado boulder collaborative agreement university gilead expects retain remaining shares gilead recognize revenue related warrant readily determinable fair value time transaction see prospective accounting pronouncement caption note description future accounting treatment warrant gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued fujisawa company 's rights market ambisome subject agreement company fujisawa healthcare inc successor fujisawa usa inc fujisawa terms fujisawa agreement amended fujisawa company copromote ambisome united states fujisawa sole marketing rights ambisome canada company exclusive marketing rights ambisome rest world provided company pays royalties fujisawa connection sales significant asian markets including japan connection us sales fujisawa purchases ambisome company cost sales canada fujisawa purchases ambisome cost plus specified percentage fujisawa collects payments sale ambisome united states canada company receives fujisawa 's gross profits sale ambisome united states gross profits include deduction cost goods sold giving company current effective royalty rate approximately fujisawa 's net sales ambisome united states connection agreement company fujisawa gilead recorded royalty revenue million million million sumitomo september company sumitomo pharmaceuticals co ltd sumitomo entered agreement sumitomo license pursuant sumitomo agreed develop market ambisome japan terms sumitomo license sumitomo paid company initial million licensing fee less withholding taxes million october million milestone payment less withholding taxes million march sumitomo also required make additional payments company certain clinical commercial milestones met pay company royalties japanese ambisome sales sumitomo license gilead obligated provide certain quantity ambisome sumitomo charge ambisome yet approved marketing japan subsequent cumulative effect change accounting principle recorded effective first quarter resulting adoption sab gilead recognizing initial license fee remaining free supply arrangement period currently expected next five years net impact change accounting principle sumitomo license increase net loss million cumulative effect change accounting principle charge million contract revenue million related initial licensing fee sumitomo recognized contract revenue remaining million related deferred revenue december recognized contract revenue remaining free supply obligation period hoffmannla roche september gilead entered collaboration agreement f hoffmannla roche ltd hoffmannla roche inc collectively roche develop commercialize therapies treat prevent viral influenza roche agreement roche agreement roche received exclusive worldwide rights gilead 's proprietary influenza neuraminidase inhibitors roche made initial license fee payment gilead million upon achieving certain gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued developmental milestones gilead earned cash payments million gilead recognized total million additional milestone payments due commencement certain clinical trials japan filing application market tamiflu european union filing subsequent approval market tamiflu united states gilead recognized million contract revenue milestone payments roche related tamiflu milestones achieved year milestones included filing regulatory approval japan treatment influenza japanese approval application filing us regulatory approval prevention influenza receipt approval us subsequent cumulative effect change accounting principle recorded effective first quarter resulting adoption sab gilead recognized initial license fee remaining research development period ended first quarter net impact change accounting initial license fee zero cumulative effect change accounting principle related roche license fee million charge results operations offset additional contract revenue million also recognized first quarter remaining deferred revenue related roche initial license fee december december gilead entitled additional cash payments roche million upon roche achieving additional developmental regulatory milestones addition roche required pay gilead royalties net product sales gilead began receiving royalties roche 's sales tamiflu first quarter recorded total million tamiflu royalties year tamiflu royalties recorded company recognizes royalty revenue roche quarter following quarter related tamiflu sales occur roche agreement roche also reimburses company related rd costs program funding costs quarterly generally advance based annual budget reimbursements included contract revenue company incurs related rd costs amounts incurred company excess amounts funded may also reimbursed subject roche 's approval event revenue recognized approval obtained conversely amounts funded roche exceed company 's related rd costs company may required repay excess funding roche company recorded contract revenue rd reimbursements related roche agreement approximately million million million million recorded revenue included million attributable rd expenses incurred fourth quarter subject roche 's approval december expenses approved reimbursement recognized contract revenue except million rd costs related roche agreement approximate reimbursement revenue year presented included rd expenses pharmacia august company pharmacia corporation pharmacia entered license supply agreement pharmacia agreement market vistide countries outside united states terms pharmacia agreement pharmacia paid gilead initial license fee million gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued subsequent cumulative effect change accounting principle recorded effective first quarter gilead recognizing initial license fee straightline basis supply arrangement period sixteen years agreement date net impact change accounting principle pharmacia agreement increase net loss million cumulative effect change accounting principle related initial license fee pharmacia million charge results operations additional contract revenue million recognized subsequent accounting change remaining million related deferred revenue expected recognized straightline basis contract revenue remaining supply period twelve years second quarter vistide approved marketing european union european commission triggered additional cash milestone payment million pharmacia company also result achieving milestone second quarter company issued pharmacia purchased shares series b convertible preferred stock approximately million per share preferred stock automatically converted shares common stock additional information preferred stock see note terms pharmacia agreement related agreements covering expanded access programs vistide outside united states gilead responsible maintaining cidofovir patent portfolio supplying pharmacia bulk cidofovir used manufacture finished vistide product gilead entitled receive royalty based upon pharmacia 's sales vistide gilead receives portion royalty upon shipping either bulk drug substance vistide pharmacia remainder upon pharmacia 's sale vistide third parties royalties gilead receives product sold third parties recorded deferred revenue thirdparty sales occur december company recorded balance sheet approximately million deferred revenue million december company recognized royalty revenue sales vistide outside united states pharmacia million million million somalogic november gilead somalogic inc somalogic entered agreement whereby gilead assigned somalogic sole exclusive license certain intellectual property related selex process diagnostic purposes including patents patent applications terms agreement somalogic required pay gilead total million two nonrefundable installments first million paid november included contract revenue year ended december remaining million reported deferred revenue december received recorded contract revenue gilead ongoing research funding obligations agreement schering ag company entered collaborative research agreement schering research agreement license agreement schering license agreement schering ag schering research agreement schering ag funded research gilead discovery gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued development aptamers vivo diagnostic agents level funding agreement varied annually high million million received recorded contract revenue schering research agreement expired company expect receive additional payments thereunder schering license agreement schering ag right develop commercialize aptamers vivo diagnostic agents radiotherapeutics discovered developed schering research agreement schering ag required make milestone royalty payments company upon commercialization sale products developed collaboration company milestone payments one product total million triggered filing investigational new drug application initiation phase iii clinical trials filing nda approval product commercial sale schering license agreement still effect december permits company develop commercialize aptamers discovered schering research agreement outside field vivo diagnostic agents radiotherapeutics subject royalty payments schering ag isis pharmaceuticals december gilead isis pharmaceuticals inc isis entered agreement gilead sold isis certain intellectual property including patents patent applications covering antisense chemistry antisense drug delivery systems terms agreement isis required pay gilead total million four nonrefundable installments first installment million paid gilead december second installment million paid december third installment million paid december remaining million payable december total sale price million included contract revenue year ended december gilead ongoing research funding obligations agreement glaxosmithkline december gilead entered agreement glaxo wellcome glaxosmithkline glaxo giving gilead rights gs l novel antitumor compound gilead developing gs l liposome evaluating preclinical studies agreement gilead exclusive worldwide rights develop commercialize gs l indications malaria gilead paid glaxo upfront fee included rd expense may required make additional payments glaxo certain developmental goals related regulatory approval achieved additionally product successfully commercialized gilead would required pay glaxo percentage product 's net sales agreement expires ten years first commercial sale product date last related patent expires may gilead entered threepart collaboration glaxo glaxo received nonexclusive right use gilead 's proprietary selex process target validation b gilead received exclusive rights subject glaxo 's right elect participate activities develop commercialize nx liposomal formulation glaxo 's proprietary topoisomerase inhibitor lurtotecan c glaxo acquired shares gilead common stock million private offering december collaboration license agreement gilead sciences inc notes consolidated financial statements continued december collaborative arrangements contracts continued modified revised terms agreement glaxo waived right participate development commercialization nx right receive royalties giving gilead exclusive rights compound exchange gilead agreed increase milestone payments glaxo upon achieving certain regulatory approvals july gilead entered collaborative research agreement glaxo respect gilead 's antisense technology terms glaxo agreement amended time company received million reported contract revenue fund research rd costs reimbursed glaxo approximate related revenue included rd expense agreement related funding terminated june iocbrega gilead entered agreements institute organic chemistry biochemistry academy sciences czech republic rega stichting iocbrega relating certain nucleotide compounds discovered two institutions agreements gilead received exclusive right manufacture use sell nucleotide compounds gilead obligated pay iocbrega percentage net revenues received sales products containing compounds subject minimum royalty payments compounds covered agreement include cidofovir adefovir dipivoxil tenofovir df exclude tamiflu compounds gilead clinical development gilead currently makes quarterly payments iocbrega based percentage vistide sales marketing approval received fda adefovir dipivoxil tenofovir df gilead would obligated pay additional amounts iocbrega upon future sales products december agreements iocbrega amended provide reduced royalty rate future sales adefovir dipivoxil tenofovir df return upfront payment gilead million plus withholding taxes approximately million upon signing agreement payment recorded longterm prepaid royalty classified noncurrent assets balance sheet december recognized royalty expense expected commercial life related products fda approval obtained sales products commence southern research institute december gilead entered agreement southern research institute giving gilead worldwide rights develop commercialize gs antitumor compound gilead evaluating preclinical studies terms agreement gilead paid southern research institute upfront fee included rd expense may required make additional payments southern research institute gilead achieves certain development regulatory goals gilead would also required pay southern research institute royalties net sales gs product successfully commercialized gilead sciences inc notes consolidated financial statements continued december inventories inventories summarized follows thousands december raw materials work process finished goods property plant equipment property plant equipment consist following thousands december building improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress less accumulated depreciation amortization investment unconsolidated affiliate late company established nexstar technology products division included company 's proprietary technology called product anchored sequential synthesis pass method synthesizing oligonucleotides basis products developed using selex process july company established proligo llc delaware limited liability company proligo wholly owned subsidiary transferred assets nexstar technology products division proligo proligo supplies nucleic acid peptide synthesis products pharmaceutical biopharmaceutical industry sale use laboratory research reagents therapeutic diagnostic products august company sold interest interest proligo skw americas inc skw payment interest company received million cash interest perseptive biosystems gmbh company hamburg germany hamburg company specializes manufacture nucleoside phosphoramidite monomers interest hamburg company fair market value approximately million addition skw agreed pay company million guaranteed payments discounted gain recognition purposes million performancebased milestones next gilead sciences inc notes consolidated financial statements continued december investment unconsolidated affiliate continued four years gilead received million guaranteed payments skw million gilead also received performancebased milestone payment million included contract revenue part original transaction company contributed million interest hamburg company proligo company recorded million gain connection sale skw contributed million remaining interest hamburg company proligo also connection transaction company proligo agreed proligo would manufacture oligonucleotides required company cost plus fixed percentage company purchased oligonucleotides proligo total million million purchases charged rd expense company accounts investment proligo using equity method accounting net book value investment million december million december reported noncurrent assets company 's consolidated balance sheets gilead recognized million equity proligo 's net loss representing share proligo 's loss thirteenmonth period ended december fourth quarter proligo changed fiscal year end december november gilead recorded million equity loss proligo proligo 's fiscal year ended november company recorded equity loss proligo million period august november january gilead made additional cash investment proligo million maintain ownership interest proligo october gilead also made million cash investment proligo maintain ownership interest gilead commitments provide additional funding proligo longterm obligations longterm obligations consist following thousands december capital lease obligations monthly installments interest rates ranging fixed rate debt monthly installments secured equipment interest rates ranging total longterm obligations less current portion longterm obligations due one year gilead sciences inc notes consolidated financial statements continued december longterm obligations continued maturities longterm obligations including capital lease obligations follows thousands year less amount representing interest total terms various debt agreements require company comply certain financial operating covenants december company compliance covenants convertible subordinated notes debentures december gilead issued million convertible subordinated notes due december private offering jp morgan co lehman brothers morgan stanley dean whitter resold notes private institutional investors notes convertible total shares gilead common stock per share conversion price higher gilead 's common stock price note 's issue date notes redeemable whole part option company time december specified redemption prices plus accrued interest debt issuance costs million incurred connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual term notes third quarter gilead issued million convertible subordinated debentures due private offering sbc warburg inc oppenheimer co inc resold debentures group private investors debentures issued pursuant indenture convertible total shares gilead common stock per share debentures redeemable whole part option company time august specified redemption prices plus accrued interest gilead called debentures redemption august cash price per principal amount debentures outstanding plus accrued interest redemption price provided original debenture indenture entire million principal amount debentures outstanding time converted newly issued shares gilead common stock prior august deferred debt issuance costs million related debentures charged additional paid capital connection conversion debentures common stock gilead sciences inc notes consolidated financial statements continued december commitments contingencies leases arrangements company entered various longterm noncancelable operating leases facilities foster city san dimas california boulder colorado leases foster city san dimas expire various dates leases boulder expire leases two fiveyear renewal options exception one lease foster city expires contains renewal options company operating leases sales marketing administrative facilities europe australia various terms miscellaneous equipment leases rent expense net sublease income company 's operating leases totaled approximately million million million company entered capital leases finance equipment purchases facilities improvements title assets acquired lease lines credit resides lessor company option purchase assets end lease terms fair market value leases remaining terms three years december additional amounts available agreements aggregate noncancelable future minimum rental payments operating capital leases net aggregate future minimum rentals received company noncancelable subleases follows thousands operating leases net years ending december noncancelable subleases capital leases thereafter less amount representing interest total capital lease obligations less current portion capital lease obligations due one year company placed million bank escrow deposit secure aggregate future payments due one facilities leases december total million secured deposit contingent liability connection august sale majority interest proligo subsidiary described note company transferred certain property equipment net book value gilead sciences inc notes consolidated financial statements continued december commitments contingencies continued million proligo majority property equipment financed leased company accordance capital leases described concurrent transfer property equipment company transferred underlying debt proligo pursuant various sublease consent assignment agreements collectively sublease agreements result company required pay debt financing lease liabilities financial institutions lessors directly proligo 's share liabilities proligo required reimburse company amounts bound terms conditions company 's agreements financial institutions lessors proligo default obligations sublease agreements company would continue liable amounts outstanding date default however event skw would obligated reimburse company amounts paid december proligo current respect reimbursements company balance proligo 's future lease debt obligations sublease agreements million additionally company proligo entered assignment assumption consent agreements agreements landlords two laboratory facilities proligo occupies agreements proligo assumed obligations landlords company remains contingently liable event default total unpaid amount operating lease commitments december approximately million gilead subleased certain facilities primarily california sublessees default obligations subleases company would primarily liable original lessor total amount due subleases december million line credit september company entered unsecured bank line credit million terms line credit company required maintain certain financial ratios compliance required ratios december also limitations company 's ability incur additional debt engage certain significant transactions credit agreement includes foreign exchange facility renegotiated december subsequently extended april amounts outstanding agreement either december legal proceedings august company elan corporation plc elan successor company liposome company inc reached settlement settlement agreement companies agreed dismiss legal proceedings involving ambisome gilead 's liposomal formulation amphotericin b settlement agreement elan granted company immunity suit connection worldwide production sales ambisome worldwide right use two patents terms settlement agreement gilead made initial payment elan million required make payments beginning based ambisome sales next several years payments subject certain minimum maximum amounts company recorded accounting charges million million represented gilead sciences inc notes consolidated financial statements continued december commitments contingencies continued net present value future minimum payments million represented initial cash payment beginning gilead records expense quarter based difference future minimum payments expense recorded addition beginning company recognizing cost goods sold difference minimum maximum payments gilead expect difference future minimum maximum payments elan material company involved time time legal proceedings arising ordinary course business opinion management none matters expected material adverse effect financial position operations company based factors currently known management stockholders ' equity stock split february gilead completed twoforone stock split effected form stock dividend stockholders record february accordingly share per share amounts periods presented restated retroactively reflect split preferred stock company shares authorized preferred stock issuable series company 's board directors board authorized determine designation powers preferences rights series company reserved shares preferred stock potential issuance preferred share purchase rights plan june company issued shares series b convertible preferred stock preferred stock pharmacia approximately million per share july average closing price gilead 's common stock thirty days ended event triggered automatic conversion preferred stock owned pharmacia company 's common stock accordingly preferred stock converted shares common stock price per share july preferred stock outstanding december employee stock purchase plan gilead 's employee stock purchase plan espp employees purchase shares gilead common stock based percentage compensation purchase price per share must equal least lower percent market value date offered date purchased total shares common stock reserved issuance espp december shares total shares reserved issued espp shares december emerging issues task force eitf issue accounting increased share authorizations irs section employee stock purchase plan apb opinion provides new shares authorized existing section employee stock purchase plans may give rise gilead sciences inc notes consolidated financial statements continued december stockholders ' equity continued compensation expense circumstances specified accounting standard gilead recognized compensation expense million related espp share authorization approved accordance provisions eitf issue future years company required recognize additional compensation expense related share authorization stock option plans december gilead adopted incentive stock option plan supplemental stock option plan issuance common stock employees consultants scientific advisors april board approved granting certain additional nonqualified stock options terms conditions substantially similar granted supplemental stock option plan none options described exercise prices less fair value underlying stock date grant options vest five years pursuant formula determined board expire ten years shares available grant future options plans november gilead adopted stock option plan plan issuance common stock employees consultants options issued plan shall discretion board either incentive stock options nonqualified stock options may plan amended exercise price stock options must least equal fair value gilead 's common stock date grant options vest five years pursuant formula determined board expire ten years may shareholders approved amendment plan increased total number authorized shares plan december shares available grant future options plan november gilead adopted nonemployee directors ' stock option plan directors ' plan issuance common stock nonemployee directors pursuant predetermined formula exercise price options granted directors ' plan must least equal fair value gilead 's common stock date grant options vest five years date grant quarterly five percent installments expire ten years december shares available grant future options directors ' plan nexstar 's stock plans include stock option plan plan incentive stock plan director option plan collectively nexstar plans options pursuant stock option plan incentive stock plan issued outstanding july converted options purchase gilead common stock result merger remain subject original terms conditions options outstanding director option plan became fully vested close merger exercisable period months thereafter shares available grant future options nexstar plans nexstar 's plan allows certain option holders execute cashless exercises options cashless exercise transaction option holder specifies many shares exercised company issues specified number shares less number would required cover gilead sciences inc notes consolidated financial statements continued december stockholders ' equity continued exercise price based fair value stock exercise date several option holders performed cashless exercises result option awards considered variable therefore company recognized compensation expense million million amount million relates exercised options remaining million relates options remain outstanding plan december following table summarizes activity gilead nexstar stock option plans three years period ended december option grants presented table exercise prices less fair value underlying stock grant date shares thousands year ended december weighted weighted weighted average average average exercise exercise exercise shares price shares price shares price outstanding beginning year granted forfeited exercised outstanding end year exercisable end year weighted average fair value options granted following summary gilead options outstanding options exercisable december options thousands options outstanding options exercisable weighted average weighted remaining average weighted options contractual exercise options average range exercise prices outstanding life years price exercisable exercise price total pro forma disclosures table presents combined net loss basic diluted net loss per common share compensation cost gilead nexstar stock option plans espp gilead sciences inc notes consolidated financial statements continued december stockholders ' equity continued determined based estimated fair value awards plans grant purchase date year ended december pro forma net loss thousands pro forma basic diluted net loss per share fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option pricing model company used multiple option approach following assumptions year ended december expected life years vesting date stock options espp discount rate stock options espp volatility expected dividend yield nexstar 's volatility rate weighted average estimated fair value espp shares purchased preferred share purchase rights plan november company adopted preferred share purchase rights plan plan provides distribution preferred stock purchase right dividend share gilead common stock held record close business december purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group company 's common stock purchase rights permit holders holder purchase gilead common stock discount market price time upon payment exercise price specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade gilead common stock october board directors approved amendment purchase rights plan amendment provided among things increase exercise price right gilead sciences inc notes consolidated financial statements continued december stockholders ' equity continued plan extension term plan november october comprehensive income following reclassification adjustments required avoid doublecounting net realized gains losses sales securities previously included comprehensive income prior sales securities thousands year ended december net gain loss sales securities included interest income comprehensive income net unrealized gain loss arising year reclassification adjustment net unrealized gain loss reported comprehensive income balance accumulated comprehensive loss reported balance sheet consists following components thousands december net unrealized gain loss availableforsale securities cumulative loss foreign currency translation accumulated comprehensive loss gilead sciences inc notes consolidated financial statements continued december disclosures segments enterprise related information company determined one reportable segment management organized business along functional lines product sales revenues consisted following thousands year ended december ambisome daunoxome vistide following table summarizes revenues external customers collaborative partners geographic region revenues attributed countries based location customer collaborative partner thousands year ended december united states united kingdom switzerland germany italy spain france european countries countries consolidated total december net book value company 's property plant equipment million approximately assets located united states december net book value property plant equipment million approximately assets located united states product sales one distributor accounted approximately total revenues total revenues fujisawa healthcare inc included product sales royalties approximately total revenues less revenues roche including royalties milestone payments reimbursement research development expenses accounted approximately total revenues gilead sciences inc notes consolidated financial statements continued december income taxes company deferred provision income taxes current provision income taxes consisted following thousands year ended december current provision federal state foreign foreign pretax loss income million million million difference provision taxes income amount computed applying federal statutory income tax rate income provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle explained thousands year ended december loss provision income taxes equity loss unconsolidated affiliate cumulative effect change accounting principle tax federal statutory rate unbenefitted losses december company us federal net operating loss carryforwards million state net operating loss carryforwards million federal net operating loss carryforwards expire various dates beginning utilized state net operating loss carryforwards expire various dates utilized utilization net operating losses may subject annual limitation due ownership change limitations provided internal revenue code similar state provisions annual limitation may result expiration net operating losses credits utilization deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax gilead sciences inc notes consolidated financial statements continued december income taxes continued purposes significant components company 's deferred tax assets liabilities december follows thousands december net operating loss carryforwards research credits capitalized rd california net total deferred tax assets valuation allowance net deferred tax assets recognized valuation allowance increased million year ended december million year ended december approximately million valuation allowance december relates tax benefits stock option deductions credited additional paidin capital realized retirement savings plan december gilead maintained two separate retirement savings plans eligible employees may defer compensation income tax purposes section k internal revenue code one plan primarily covers nexstar employees nexstar plan plan primarily covers gilead 's remaining eligible employees gilead plan nexstar plan employee contributions may exceed eligible annual compensation addition nexstar plan includes company match employee contributions maximum eligible annual compensation annual maximum company match december approximately million representing shares gilead common stock held nexstar plan trust plan participants effective february contributions nexstar plan may invested company 's common stock gilead plan employees may contribute eligible annual compensation effective january gilead began making matching contributions gilead plan company contributes employee 's first contributions annual maximum company match company 's total matching contribution nexstar plan gilead plan million company 's matching contribution related nexstar plan million million january nexstar plan terminated combined gilead plan related party transactions gilead paid aggregate million pharmaresearch corporation contract research organization services rendered connection clinical studies chairman gilead 's board directors senior advisor investment fund owns controlling interest gilead sciences inc notes consolidated financial statements continued december related party transactions continued pharmaresearch corporation gilead 's payments pharmaresearch corporation million million subsequent events cubist collaboration january gilead entered agreement cubist pharmaceuticals inc cubist relating cubist 's antibacterial compound daptomycin including cidecin intravenous formulation compound currently phase iii clinical trials treatment bacterial infections terms agreement gilead paid cubist upfront license fee million received exclusive commercial rights compound sixteen european countries gilead 's territory cubist continue responsible worldwide clinical development cidecin gilead responsible regulatory filings marketing sales product within gilead 's territory gilead may make additional payments cubist million certain clinical regulatory milestones reached additionally cidecin successfully commercialized gilead 's territory gilead pay cubist royalty net sales product increase authorized shares common stock february special meeting stockholders stockholders approved amendment gilead 's certificate incorporation increase number authorized shares common stock quarterly results unaudited following table thousands except per share amounts st quarter nd quarter rd quarter th quarter restated restated restated total revenues total costs expenses loss cumulative effect change accounting principle cumulative effect change accounting principle net loss basic diluted amounts per share loss cumulative effect change accounting principle cumulative effect change accounting principle net loss gilead sciences inc notes consolidated financial statements continued december quarterly results unaudited continued previously reported st quarter nd quarter rd quarter previously reported total revenues total costs expenses net loss basic diluted net loss per share st quarter nd quarter rd quarter th quarter total revenues total costs expenses net loss basic diluted net loss per share year ended december gilead adopted sab reported change cumulative effect change accounting principle accounting change adopted fourth quarter effective first quarter first three quarters restated retroactively reflect change quarterly information originally reported presented caption previously reported february gilead completed twoforone stock split effected form stock dividend stockholders record february accordingly share per share amounts periods presented restated retroactively reflect split gilead sciences inc schedule ii valuation qualifying accounts thousands additions balance balance beginning charged charged end period expense deductions period year ended december allowance doubtful accounts valuation allowance deferred tax assets year ended december allowance doubtful accounts valuation allowance deferred tax assets year ended december allowance doubtful accounts allowance noncurrent assets valuation allowance deferred tax assets august major customer company filed bankruptcy protection chapter us bankruptcy code total outstanding receivable million customer december reserved company collected approximately million amount assigning claim third party company reversed portion allowance doubtful accounts longer deemed necessary company accepted full settlement outstanding note receivable fully reserved balance sheet charged deferred tax benefit signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized gilead sciences inc john c martin john c martin president chief executive officer power attorney know persons presents person whose signature appears constitutes appoints john c martin mark l perry true lawful attorneysinfact agents full power substitution resubstitution name place stead capacities sign amendments report file exhibits thereto documents connection therewith securities exchange commission granting unto said attorneysinfact agents full power authority perform every act thing requisite necessary done connection therewith fully intents purposes might could person hereby ratifying confirming said attorneysinfact agents substitute substitutes may lawfully cause done virtue hereof pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date john c martin president chief executive officer director principal march john c martin executive officer vice president chief sharon surreybarbari financial officer principal financial accounting march sharon surreybarbari officer james denny chairman board directors march james denny paul berg director march paul berg signatures continued signature title date etienne f davignon director march etienne f davignon gordon e moore director march gordon e moore george p shultz director march george p shultz exhibit restated certificate incorporation gilead sciences inc gilead sciences inc corporation organized existing general corporation law state delaware hereby certify follows first name corporation gilead sciences inc second corporation 's original certificate incorporation filed secretary state june third amended restated certificate incorporation corporation form attached hereto exhibit duly adopted accordance provisions sections general corporation law state delaware board directors stockholders corporation fourth amended restated certificate incorporation adopted reads full set forth exhibit attached hereto hereby incorporated reference witness whereof gilead sciences inc caused restated certificate incorporation signed president attested secretary th day january gilead sciences inc michael l riordan michael l riordan president attest james c gaither james c gaither secretaryexhibit restated certificate incorporation gilead sciences inc name corporation gilead sciences inc ii address registered office corporation state delaware orange street city wilmington county new castle delaware name registered agent corporation state delaware address corporation trust company iii purpose corporation engage lawful act activity corporation may organized general corporation law delaware iv liability directors corporation monetary damages shall eliminated fullest extent permissible delaware law b corporation authorized provide indemnification agents defined section delaware general corporation law breach duty corporation stockholders bylaw provisions agreements agents andor stockholder resolutions otherwise excess indemnification otherwise permitted section delaware general corporation law subject limitations excess indemnification set forth section delaware general corporation law c repeal modification article iv shall prospective shall affect rights article iv effect time alleged occurrence act omission act giving rise liability indemnification v corporation authorized issue two classes stock designated respectively common stock preferred stock total number shares corporation authorized issue forty million shares thirtyfive million shares shall common stock par value onetenth one cent five million shares shall preferred stock par value onetenth one cent b preferred stock may issued time time one series board directors hereby authorized filing certificate pursuant delaware general corporation law fix alter time time designation powers preferences rights shares series qualifications limitations restrictions thereof including without limitation dividend rights dividend rate conversion rights voting rights rights terms redemption including sinking fund provisions redemption price prices liquidation preferences wholly unissued series preferred stock establish time time number shares constituting series designation thereof preferred stock designation increase decrease number shares series subsequent issuance shares series number shares series outstanding case number shares series shall decreased accordance foregoing sentence shares constituting decrease shall resume status prior adoption resolution originally fixing number shares series vi management business conduct affairs corporation definition limitation regulation powers corporation directors stockholders class thereof case may provided section board directors management corporation management business conduct affairs corporation shall vested board directors number directors shall constitute whole board directors shall fixed exclusively one resolutions adopted time time board directors notwithstanding provisions certificate incorporation director shall serve successor duly elected qualified death resignation removal decrease number directors constituting board directors shall shorten term incumbent director b removal prior qualifying record date subject limitations imposed law board directors individual director may removed office time without cause affirmative vote holders majority outstanding voting stock hereinafter defined ii qualifying record date subject limitations imposed law section bi article vi shall longer apply board directors individual director may removed office time cause affirmative vote holders majority outstanding voting stock b without cause affirmative vote holders least outstanding voting stock c vacancies vacancies board directors resulting death resignation disqualification removal causes shall filled either affirmative vote holders majority voting stock voting together single class ii affirmative vote majority remaining directors office even though less quorum board directors newly created directorships resulting increase number directors shall unless board directors determines resolution newly created directorship shall filled stockholders filled affirmative vote directors office even though less quorum board directors director elected accordance preceding sentence shall hold office remainder full term class directors new directorship created vacancy occurred director 's successor shall elected qualified section cumulative voting prior date upon corporation longer subject section california corporations code qualifying record date every stockholder entitled vote election directors corporation may cumulate stockholder 's votes give one candidate number votes equal number directors elected multiplied number votes stockholder 's shares otherwise entitled distribute stockholder 's votes principle among many candidates stockholder thinks fit stockholder however may cumulate stockholder 's votes one candidates unless names candidates properly placed nomination accordance bylaws corporation prior voting ii stockholder given advance notice corporation intention cumulate votes accordance bylaws iii stockholder given proper notice stockholders meeting prior voting stockholder 's intention cumulate stockholder 's votes stockholder given proper notice stockholders may cumulate votes candidates properly placed nomination candidates receiving highest number votes shares entitled voted number directors elected shares shall declared elected b qualifying record date cumulative voting shall longer available stockholders corporation section general bylaws may altered amended new bylaws adopted affirmative vote least voting power thenoutstanding shares voting stock furtherance limitation power conferred statute board directors expressly authorized adopt amend supplement repeal bylaws board directors may time time make amend supplement repeal bylaws provided however stockholders may change repeal bylaw adopted board directors requisite affirmative vote stockholders set forth bylaws provided amendment supplement bylaws adopted board directors shall vary conflict amendment supplement thus adopted stockholders b directors corporation need elected written ballot unless bylaws provide c action shall taken stockholders corporation except annual special meeting stockholders called accordance bylaws action shall taken stockholders written consent advance notice stockholder nominations election directors business brought stockholders meeting stockholders corporation shall given manner provided bylaws corporation vii holder shares stock corporation shall preemptive right except rights expressly provided contract purchase subscribe receive shares class series thereof stock corporation whether hereafter authorized warrants options bonds debentures securities convertible exchangeable carrying right purchase share class series thereof stock additional shares stock warrants options bonds debentures securities convertible exchangeable carrying right purchase shares class series thereof stock may issued disposed board directors persons terms lawful consideration discretion shall deem advisable corporation shall contract agreed viii corporation perpetual existence ix corporation reserves right amend alter change repeal provision contained certificate incorporation manner hereafter prescribed statute except provided paragraph b article ix rights conferred upon stockholders herein granted subject reservation b notwithstanding provisions certificate incorporation provision law might otherwise permit lesser vote vote addition affirmative vote holders particular class series voting stock required law certificate incorporation preferred stock designation affirmative vote holders least voting power thenoutstanding shares voting stock voting together single class shall required alter amend repeal article vi article vii article ix certificate amendment restated certificate incorporation gilead sciences inc john c martin mark l perry hereby certify follows one name corporation gilead sciences inc two restated certificate incorporation gilead sciences inc filed secretary state state delaware january three duly elected acting president secretary respectively gilead sciences inc delaware corporation four board directors gilead sciences inc acting accordance provisions sections general corporation law state delaware adopted resolutions amend restated certificate incorporation follows article v shall amended restated read entirety follows v corporation authorized issue two classes stock designated respectively common stock preferred stock total numbers shares corporation authorized issue one hundred five million shares one hundred million shares shall designated common stock par value onetenth one cent five million shares shall designated preferred stock par value onetenth one cent b preferred stock may issued time time one series board directors hereby authorized filing certificate pursuant delaware general corporation law fix alter time time designation powers preferences rights shares series qualifications limitations restrictions thereof including without limitation dividend rights dividend rate conversion rights voting rights rights terms redemption including sinking fund provisions redemption price prices liquidation preferences wholly unissued series preferred stock establish time time number shares constituting series designation thereof preferred stock designation increase decrease number shares series outstanding case number shares series shall decreased accordance foregoing sentence shares constituting decrease shall resume status prior adoption resolution originally fixing number shares series five thereafter pursuant resolution board directors certificate amendment submitted stockholders corporation approval duly adopted accordance provisions section general corporation law state delaware six provisions restated certificate incorporation shall remain full force effect witness whereof gilead sciences inc caused certificate amendment signed president attested secretary th day july john c martin john c martin president mark l perry mark l perry secretary certificate amendment amended restated certificate incorporation gilead sciences inc john c martin mark l perry hereby certify follows one name corporation gilead sciences inc two date amended restated certificate incorporation corporation filed secretary state state delaware january certificate amendment amended restated certificate incorporation filed secretary state state delaware july three duly elected acting president secretary respectively gilead sciences inc delaware corporation four board directors corporation acting accordance provisions section general corporation law state delaware adopted resolutions amend amended restated certificate incorporation corporation following form article v shall amended restated read entirety follows v corporation authorized issue two classes stock designated respectively common stock ' preferred stock ' total number shares corporation authorized issue five hundred five million shares five hundred million shares shall common stock par value onetenth one cent five million shares shall preferred stock par value onetenth one cent b preferred stock may issued time time one series board directors hereby authorized filing certificate pursuant delaware general corporation law fix alter time time designation powers preferences rights shares series qualifications limitations restrictions thereof including without limitation dividend rights dividend rate conversion rights voting rights rights terms redemption including sinking fund provisions redemption price prices liquidation preferences wholly unissued series preferred stock establish time time number shares constituting series designation thereof preferred stock designation increase decrease number shares series outstanding case number shares series shall decreased accordance foregoing sentence shares constituting decrease shall resume status prior adoption resolution originally fixing number shares series five thereafter pursuant resolution board directors certificate amendment submitted stockholders corporation approval duly adopted accordance provision section general corporation law state delaware six stock provisions amended restated certificates incorporation shall remain full force effect witness whereof gilead sciences inc caused certificate amendment signed president attested secretary day february gilead sciences inc john c martin john c martin president attest mark l perry mark l perry secretary exhibit gilead sciences inc stock option plan adopted november amended april amended april amended october amended restated january amended march amended restated april termination date april purposes plan initially adopted november amended october initial plan initial plan amended restated entirety effective january amended march subject approval stockholders company plan hereby amended restated entirety effective april terms plan excluding previously amended provision relating exercise price nonstatutory stock options shall apply options granted pursuant initial plan b purpose plan provide means selected employees directors consultants company affiliates may given opportunity purchase stock company c company means plan seeks retain services persons employees consultants company secure retain services new employees consultants provide incentives persons exert maximum efforts success company company intends options issued plan shall discretion board committee responsibility administration plan delegated pursuant subsection c either incentive stock options nonstatutory stock options options shall separately designated incentive stock options nonstatutory stock options time grant form issued pursuant section separate certificate certificates issued shares purchased exercise type option definitions affiliate means parent corporation subsidiary corporation company whether hereafter existing terms defined sections e f respectively code b board means board directors company c code means internal revenue code amended committee means committee appointed board accordance subsection c plan e company means gilead sciences inc delaware corporation f consultant means person including advisor engaged company affiliate render services compensated services provided term consultant shall include directors paid director 's fee company otherwise compensated company services directors term consultant shall include member board directors affiliate g continuous service formerly designated continuous status employee consultant means optionee 's service company affiliates interrupted terminated optionee 's continuous service shall deemed terminated merely change capacity optionee renders service company itsaffiliates change entity optionee renders service provided interruption termination optionee 's continuous service example change status employee company consultant director company member board directors affiliate constitute interruption continuous service board chief executive officer company party 's sole discretion may determine whether continuous service shall considered interrupted case leave absence approved board chief executive officer company including sick leave military leave personal leave h covered employee means chief executive officer four highest compensated officers company total compensation required reported shareholders exchange act determined purposes section code director means member board j disability means total permanent disability defined section e code k employee means person including officers directors employed company affiliate company neither service director payment director 's fee company shall sufficient constitute employment company l exchange act means securities exchange act amended fair market value means date value common stock company determined follows common stock listed established stock exchange national market system including without limitation national market system national association securities dealers inc automated quotation nasdaq system fair market value share common stock shall closing sales price stock closing bid sales reported quoted system exchange exchange greatest volume trading common stock last market trading day prior day determination reported wall street journal source board deems reliable ii common stock quoted nasdaq system national market system thereof regularly quoted recognized securities dealer selling prices reported fair market value share common stock shall mean high bid high asked prices common stock last market trading day prior day determination reported wall street journal source board deems reliable iii absence established market common stock fair market value shall determined good faith board n incentive stock option means option intended qualify incentive stock option within meaning section code regulations promulgated thereunder nonemployee director means director either current employee officer company parent subsidiary receive compensation directly indirectly company parent subsidiary services rendered consultant capacity director except amount disclosure would required item regulation sk promulgated pursuant securities act possess interest transaction disclosure would required item regulation sk engaged business relationship disclosure would required item b regulation sk ii otherwise considered nonemployee director purposes rule b p nonstatutory stock option means option intended qualify incentive stock option q officer means person officer company within meaning section exchange act rules regulations promulgated thereunder r option means stock option granted pursuant plan option agreement means written agreement company optionee evidencing terms conditions individual option grant option agreement subject terms conditions plan optioned stock means common stock company subject optionu optionee means person holds outstanding option v outside director means director either current employee company affiliated corporation within meaning treasury regulations promulgated section code former employee company affiliated corporation receiving compensation prior services benefits tax qualified pension plan officer company affiliated corporation time currently receiving direct indirect remuneration company affiliated corporation services capacity director ii otherwise considered outside director purposes section code w plan means stock option plan x rule b means rule b exchange act successor rule b effect discretion exercised respect plan administration board shall administer plan unless board delegates administration committee provided subsection c b board shall power subject within limitations express provisions plan determine time time persons eligible plan shall granted options option shall granted whether option incentive stock option nonstatutory stock option provisions option granted need identical including time times option may exercised whole part number shares option shall granted person ii construe interpret plan options granted establish amend revoke rules regulations administration board exercise power may correct defect omission inconsistency plan option agreement manner extent shall deem necessary expedient make plan fully effective iii amend plan provided section iv generally exercise powers perform acts board deems necessary expedient promote best interests company c board may delegate administration plan committee committees one members board discretion board committee may consist solely two outside directors accordance code section solely two nonemployee directors accordance rule b exchange act administration delegated committee committee shall connection administration plan powers theretofore possessed board references plan board shall thereafter committee subject however resolutions inconsistent provisions plan may adopted time time board board may abolish committee time revest board administration plan within scope authority board committee may delegate committee one members board authority grant options eligible persons subject section exchange act andor either covered employees expected covered employees time recognition income resulting option ii persons respect company wishes comply section code shares subject plan subject provisions section relating adjustments upon changes stock stock may sold pursuant options shall exceed aggregate ten million seven hundred fifty thousand shares company 's common stock option shall reason expire otherwise terminate whole part without exercised full stock purchased option shall revert become available issuance plan b stock subject plan may unissued shares reacquired shares bought market otherwise eligibilitya incentive stock options may granted employees nonstatutory stock options may granted employees directors consultants b person shall eligible grant incentive stock option time grant person owns deemed pursuant section code stock possessing ten percent total combined voting power classes stock company affiliates unless exercise price option least one hundred ten percent fair market value stock date grant option exercisable expiration five years date grant c subject provisions section relating adjustments upon changes stock person shall eligible granted options covering five hundred thousand shares company 's common stock calendar year option provisions option shall form shall contain terms conditions board shall deem appropriate provisions separate options need identical option shall include incorporation provisions hereof reference option otherwise substance following provisions term option shall exercisable expiration ten years date granted b price exercise price exercise price incentive stock option nonstatutory stock option shall less one hundred percent fair market value stock subject option date option granted ii authority reprice without consent stockholders company board shall authority effect repricing outstanding options plan andor b cancellation outstanding options plan grant substitution therefor new options plan covering different numbers shares common stock c consideration purchase price stock acquired pursuant option shall paid extent permitted applicable statutes regulations either cash time option exercised ii discretion board committee time grant option delivery company common stock company b according deferred payment arrangement except payment common stock 's par value defined delaware general corporation law shall made deferred payment arrangement may include without limiting generality foregoing use common stock company person option granted option transferred pursuant subsection c form legal consideration may acceptable board case deferred payment arrangement interest shall compounded least annually shall charged minimum rate interest necessary avoid treatment interest applicable provisions code amounts amounts stated interest deferred payment arrangement transferability incentive stock option shall transferable except laws descent distribution shall exercisable lifetime person option granted person nonstatutory stock option incentive stock option may transferred extent provided option agreement provided option agreement expressly permit transfer nonstatutory stock option nonstatutory stock option shall transferable except laws descent distribution shall exercisable lifetime person option granted person person option granted may delivering written notice company form satisfactory company designate third party event death optionee shall thereafter entitled exercise option e vesting total number shares stock subject option may need allotted periodic installments may need equal option agreement may provide time time installment periods option may become exercisable vest respect shares allotted period may exercised respect shares allotted period andor prior period option became vested fully exercised remainder term option term extends beyond end installment periods option may exercised time time respect shares remaining subject option option may subject terms conditions time times may exercised may based performance criteria board may deem appropriate provisions subsection e subject option provisions governing minimum number shares option may exercised f securities law compliance company may require optionee person option transferred undersubsection condition exercising option give written assurances satisfactory company optionee 's knowledge experience financial business matters andor employ purchaser representative reasonably satisfactory company knowledgeable andexperienced financial business matters capable evaluating alone together purchaser representative merits risks exercising option give written assurances satisfactory company stating person acquiring stock subject option person 's account present intention selling otherwise distributing stock requirements assurances given pursuant requirements shall inoperative issuance shares upon exercise option registered currently effective registration statement securities act amended securities act ii particular requirement determination made counsel company requirement need met circumstances applicable securities laws company may require optionee provide representations written assurances information company shall determine necessary desirable appropriate comply applicable securities laws condition granting option optionee permitting optionee exercise option company may upon advice counsel company place legends stock certificates issued plan counsel deems necessary appropriate order comply applicable securities laws including limited legends restricting transfer stock g termination employment consulting relationship event optionee 's continuous service terminates upon optionee 's death disability optionee may exercise option within period time determined board extent optionee entitled exercise date termination event later expiration term option set forth option agreement case incentive stock option board shall determine period time event exceed ninety days date termination option granted date termination optionee entitled exercise entire option shares covered unexercisable portion option shall revert plan termination optionee exercise option within time specified option agreement option shall terminate shares covered option shall revert plan h disability optionee event optionee 's continuous service terminates result optionee 's disability optionee may exercise option within twelve months date termination shorter period specified option agreement extent optionee entitled exercise date termination event later expiration term option set forth option agreement date termination optionee entitled exercise entire option shares covered unexercisable portion option shall revert plan termination optionee exercise option within time specified herein option shall terminate shares covered option shall revert plan death optionee event death optionee option may exercised time within twelve months following date death shorter period specified option agreement event later expiration term option set forth option agreement optionee 's estate person acquired right exercise option bequest inheritance extent optionee entitled exercise option date death time death optionee entitled exercise entire option shares covered unexercisable portion option shall revert plan death optionee 's estate person acquired right exercise option bequest inheritance exercise option within time specified herein option shall terminate shares covered option shall revert plan j early exercise option may need include provision whereby optionee may elect time employee consultant exercise option part shares subject option prior full vesting option unvested shares purchased may subject repurchase right favor company restriction board determines appropriate k withholding extent provided terms option agreement optionee may satisfy federal state local tax withholding obligation relating exercise option following means combination means tendering cash payment authorizing company withhold shares shares common stock otherwise issuable optionee result exercise option delivering company owned unencumbered shares common stock company covenants company terms options company shall keep available times number shares stock required satisfy options b company shall seek obtain regulatory commission agency jurisdiction plan authority may required issue sell shares stock upon exercise options provided however undertaking shall require company register securities act either plan option stock issued issuable pursuant option reasonable efforts company unable obtain regulatory commission agency authority counsel company deems necessary lawful issuance sale stock plan company shall relieved liability failure issue sell stock upon exercise options unless authority obtained use proceeds stock proceeds sale stock pursuant options shall constitute general funds company miscellaneous board shall power accelerate time option may first exercised time option part thereof vest pursuant subsection e notwithstanding provisions option stating time may first exercised time vest b neither optionee person option transferred subsection shall deemed holder rights holder respect shares subject option unless person satisfied requirements exercise option pursuant terms c nothing plan instrument executed option granted pursuant thereto shall confer upon employee consultant optionee right continue employ company affiliate continue acting consultant shall affect right company affiliate terminate employment relationship consultant employee consultant optionee without cause extent aggregate fair market value determined time grant stock respect incentive stock options exercisable first time optionee calendar year plans company affiliates exceeds one hundred thousand dollars options portions thereof exceed limit according order granted shall treated nonstatutory stock options adjustments upon changes stock change made stock subject plan subject option merger consolidation reorganization recapitalization stock dividend dividend property cash stock split liquidating dividend combination shares exchange shares change corporate structure otherwise plan appropriately adjusted classes maximum number shares subject plan pursuant subsection maximum number shares subject award person calendar year period pursuant subsection outstanding options appropriately adjusted classes number shares price per share stock subject outstanding options b event dissolution liquidation company merger consolidation company surviving corporation reverse merger company surviving corporation shares company 's common stock outstanding immediately preceding merger converted virtue merger property whether form securities cash otherwise capital reorganization fifty percent shares company entitled vote exchanged sole discretion board extent permitted applicable law surviving corporation shall assume options outstanding plan shall substitute similar options outstanding plan ii time options may exercised shall accelerated options terminated exercised prior event iii options shall continue full force effect c notwithstanding provisions plan contrary event occurs specified subsection b change control within one month thirteen months date change control continuous service optionee terminates due involuntary termination including death disability without cause term defined voluntary termination optionee due constructive termination term defined vesting exercisability options held optionee shall accelerated reacquisition repurchase rights held company respect option shall lapse follows respect options held optionee time termination one hundred percent unvested shares covered options shall vest become exercisable reacquisition repurchase rights held company shall lapse respect one hundred percent shares still subject rights appropriate date termination notwithstanding foregoing however potential acceleration vesting exercisability options lapse reacquisition repurchase rights held company respect options would cause contemplated change control transaction would otherwise eligible accounted poolingofinterests transaction become ineligible accounting treatment generally accepted accounting principles determined company 's independent public accountants accountants prior change control acceleration shall occur purposes subsection c cause means conviction guilty plea respect plea nolo contendere charge optionee committed felony laws united states state crime involving moral turpitude including limited fraud theft embezzlement crime results intended result personal enrichment expense company affiliate ii material breach agreement entered optionee thecompany affiliate impairs company 's affiliate 's interest therein iii willful misconduct significant failure optionee perform optionee 's duties gross neglect optionee optionee 's duties iv engagement activity constitutes material conflict interest company affiliate purposes subsection c constructive termination means occurrence following events conditions change optionee 's status title position responsibilities including reporting responsibilities represents adverse change optionee 's status title position responsibilities effect time within ninety days preceding date change control time thereafter b assignment optionee duties responsibilities inconsistent optionee 's status title position responsibilities effect time within ninety days preceding date change control time thereafter c removal optionee failure reappoint reelect optionee offices positions except connection termination optionee 's continuous service cause result optionee 's disability death optionee result constructive termination ii reduction optionee 's annual base compensation failure pay optionee compensation benefits optionee entitled within five days date due iii company 's requiring optionee relocate place outside fifty mile radius optionee 's current work site except reasonably required travel business company affiliates materially greater travel requirements prior change control iv failure company continue effect without reduction benefit level andor reward opportunities material compensation employee benefit plan optionee participating time within ninety days preceding date change control time thereafter unless plan replaced plan provides substantially equivalent compensation benefits optionee b provide optionee compensation benefits aggregate least equal terms benefit levels andor reward opportunities provided employee benefit plan program practice optionee participating time within ninety days preceding date change control time thereafter v material breach company provision agreement company optionee whether pursuant plan otherwise breach cured company within fifteen days following notice optionee breach vi failure company obtain agreement satisfactory optionee successors assigns assume agree perform obligations created plan event acceleration vesting exercisability options lapse reacquisition repurchase rights held company respect options provided subsection c benefits otherwise payable optionee constitute parachute payments within meaning section g may amended replaced code ii subsection would subject excise tax imposed section may amended replaced code excise tax optionee 's benefits hereunder shall delivered lesser extent would result portion benefits subject excise tax provided however benefits hereunder shall reduced extent necessary cash amounts otherwise payable optionee constitute parachute payments returned unless company optionee otherwise agree writing determination required subsection shall made writing good faith accountants purposes making calculations required subsection accountants may make reasonable assumptions approximations concerning applicable taxes may rely reasonable good faith interpretations concerning application code company optionees shall furnish accountants information documents accountants may reasonably request order make determination subsection company shall bear costs accountants may reasonably incur connection calculations contemplated subsection amendment plan board time time time may amend plan however except provided section relating adjustments upon changes stock amendment shall effective unless approved stockholders company within twelve months adoption amendment amendment increase number shares reserved options plan ii effect repricing outstanding options plan andor b cancellation outstanding options plan grant substitution therefor new options plan covering different numbers shares common stock iii modify requirements eligibility participation plan extent modification requires stockholder approval order plan satisfy requirements section code iv modify plan way modification requires stockholder approval order plan satisfy requirements section code comply requirements rule b nasdaq securities exchange listing requirements b board may sole discretion submit amendment plan stockholder approval including butnot limited amendments plan intended satisfy requirements section code regulations promulgated thereunder regarding exclusion performancebased compensation limit corporate deductibility compensation paid certain executive officers c expressly contemplated board may amend plan respect board deems necessary advisable provide optionees maximum benefits provided provided provisions code regulations promulgated thereunder relating incentive stock options andor bring plan andor incentive stock options granted compliance therewith rights obligations option granted amendment plan shall altered impaired amendment plan unless company requests consent person option granted ii person consents writing termination suspension plan board may suspend terminate plan time unless sooner terminated plan shall terminate april date within ten years following stockholder approval amended restated plan adopted board april options may granted plan plan suspended terminated b rights obligations option granted plan effect shall altered impaired suspension termination plan except consent person option granted effective date plan plan shall become effective determined board options granted plan shall exercised unless stockholders company approved plan left blank intentionallyexhibit institute organic chemistry rega institute medical research biochemistry academy sciences katholieke universiteit leuven czech republic minderbroedersstraat flemingovo nam b leuven praha belgium czech republic attention professor dr de clercq attention dr antonin holy december license agreement gilead sciences inc gilead institute organic chemistry biochemistry integral part ceskoslovenska akademie ved iocb rega stichting vzw rega dated november amended prior date letter agreement agreement license agreement license agreement gilead sciences inc iocb rega dated december amended prior date letter agreement agreement license agreement license agreement license agreement referred collectively license agreements dear drs holy de clercq writing set forth terms upon agreed amend license agreements described amendment date used herein shall mean date last signatory letter agreement signs letter agreement agree amendment date follows following definition shall added article license agreement adefovir shall mean adefovir dipivoxil bispivaloyloxymethylphosphinylmethoxyethyladenine following definition shall added article license agreement tenofovir shall mean r pmpa tenofovir disoproxil fumarate rbisisopropoxycarbonyloxymethoxyphosphinyl methoxy propyladenine fumarate capitalized terms used section defined herein shall meanings given license agreement section iv b section iv c license agreement shall deleted replaced entirety following b five percent net sales licensed product licensed product containing adefovir licensed compound three percent net sales licensed product containing adefovir licensed compound sold gilead affiliates sublicensees manufacture use sale would license infringe valid claim licensed patents country sale except set forth following sentence respect net sales would royaltybearing set forth previous sentence licensed compound licensed product sold country third party except agreement gilead iocbrega seeking diligently enforce licensed patents gilead shall pay iocbrega total two onehalf percent net sales licensed compound licensed product contain adefovir licensed compound one onehalf percent licensed compound licensed product contain adefovir licensed compound c two onehalf percent net sales licensed product containing adefovir licensed compound sold gilead affiliates sublicensees covered licensed patents exploits technical information knowhow royalties licensed product containing adefovir licensed compound sold gilead affiliates sublicensees covered licensed patents exploits technical information knowhow capitalized terms used section defined herein shall meanings given license agreement section iv b section iv c license agreement shall deleted replaced entirety following b five percent net sales licensed product licensed product containing tenofovir licensed compound three percent net sales licensed product containing tenofovir licensed compound sold gilead affiliates sublicensees manufacture use sale would license infringe valid claim licensed patents country sale except set forth following sentence respect net sales would royaltybearing set forth previous sentence licensed compound licensed product sold country third party except agreement gilead iocbrega seeking diligently enforce licensed patents gilead shall pay iocbrega total two onehalf percent net sales licensed compound licensed product contain tenofovir licensed compound one onehalf percent licensed compound licensed product contain tenofovir licensed compound c two onehalf percent net sales licensed product containing tenofovir licensed compound sold gilead affiliates sublicensees covered licensed patents exploits technical information knowhow royalties licensed product containing tenofovir licensed compound sold gilead affiliates sublicensees covered licensed patents exploits technical information knowhow consideration agreement amend license agreement gilead pay licensed product containing adefovir provided section iocb rega together single payment one million seven hundred seventy thousand united states dollars follows gilead pay rega gilead pay iocb consideration agreement amend license agreement gilead pay licensed product containing tenofovir provided section iocb rega together single payment nine million two hundred thirty thousand united states dollars follows gilead pay rega gilead pay iocb rega iocb gilead agree section annex agreement made rega iocb gilead effective april section shall amended iocb rega shall receive amounts payable gilead instead respectively section shall otherwise remain unchanged payments section shall net deduction shall made gilead respect withholding tax payable respect thereof imposed united states america shall responsibility gilead account gilead hereby agrees indemnify hold harmless rega iocb reimburse rega iocb withholding taxes paid payable united states america respect payments section gilead shall make payments required section wire transfer immediately available funds within five business days gilead 's receipt fully countersigned copy letter agreement following accounts rega generale bank account stichting rega vzw minderbroedersstraat leuven belgium iocb ceska narodni banka praha account bank code account holder ustav organicke chemie biochemie praha flemingovo nam czech republic iocb rega agree commission royalty obligation shall owed gilead third party result payments made letter agreement except expressly provided letter agreement license agreements shall remain unchanged offer contained letter agreement shall valid letter agreement shall become binding upon us gilead receives executed counterpart letter agreement facsimile signatories listed pm pacific standard time december indicate agreement amend license agreements provisions letter agreement specified please sign return one copy letter facsimile letter agreement may executed multiple counterparts shall original shall together constitute document sincerely gilead sciences inc john c martin phd john c martin phd president chief executive officer accepted agreed accepted agreed institute organic chemistry rega stichting vzw biochemistry academy sciences czech republic dr antonin holy professor dr de clercq name dr antonin holy name professor dr de clercq date december date december exhibit subsidiaries gilead sciences inc name subsidiary country state incorporation gilead sciences limited ireland gilead sciences gmbh germany gilead sciences sarl france gilead sciences srl italy gilead sciences sa spain gilead sciences lda portugal gilead sciences ltd united kingdom gilead sciences international ltd united kingdom gilead sciences pty limited australia gilead sciences bv netherlands nexstar pharmaceuticals international inc delaware gilead irish holdings ltd irelandexhibit consent ernst young llp independent auditors consent incorporation reference registration statement form pertaining gilead sciences inc stock option plan registration statement form pertaining gilead sciences inc incentive stock option plan supplemental stock option plan stock option plan employee stock purchase plan nonemployee directors ' stock option plan registration statement form pertaining gilead sciences inc stock option plan nonemployee directors ' stock option plan employee stock purchase plan registration statement form pertaining nexstar pharmaceuticals inc incentive stock plan nexstar pharmaceuticals inc director option plan vestar inc stock option plan registration statement form gilead sciences inc related prospectus registration statement form gilead sciences inc related prospectus report dated january respect consolidated financial statements schedule gilead sciences inc included annual report year ended december ernst young llp palo alto california march exhibit consent independent accountants hereby consent inclusion annual report gilead sciences inc report dated january relating financial statements proligo llc thirteenmonth period ended december incorporated annual report pricewaterhousecoopers llp broomfield colorado march end filing edgar online inc